var title_f32_6_32864="PDA pulsed Doppler echo II";
var content_f32_6_32864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulsed Doppler tracing  in a patient with patent ductus arteriosus and left-to-right shunting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulsed Doppler tracing in a patient with a patent ductus arteriosus with a significant left-to-right shunt was obtained by positioning the sample volume in the descending aorta at the level of the diaphragm. Note the continuous run-off pattern of flow during diastole (arrows, lower panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32864=[""].join("\n");
var outline_f32_6_32864=null;
var title_f32_6_32865="Saber sheath CT";
var content_f32_6_32865=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saber sheath trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan demonstrates the characteristic narrow coronal and wide sagittal diameter of the trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32865=[""].join("\n");
var outline_f32_6_32865=null;
var title_f32_6_32866="Sodium benzoate: Pediatric drug information";
var content_f32_6_32866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium benzoate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ammonium Detoxicant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hyperammonemia Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Urea Cycle Disorder (UCD) Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Investigational use (not an FDA-approved drug): Initial loading dose: 0.25 g/kg/dose followed by 0.25 g/kg/day divided every 6-8 hours (Enns, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     If I.V. administration is necessary, see the sodium phenylacetate and sodium benzoate monograph for information about a commercially available parenteral product.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Investigational use (not an FDA-approved drug):",
"     <b>",
"      Note:",
"     </b>",
"     If I.V administration is necessary, see the sodium phenylacetate and sodium benzoate monograph for information about a commercially available parenteral product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: Initial loading dose: 0.25 g/kg/dose followed by 0.25 g/kg/day divided every 6-8 hours (Enns, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: Initial 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     followed by 5.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F247197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Powder: 454 g",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available commercially; Oral: Must be compounded using chemical powder",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy for the prevention and treatment of hyperammonemia due to suspected or proven urea cycle disorders",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F14198760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with Reye's syndrome, propionic or methylmalonic acidemia.",
"     <i>",
"      In vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites; use cautiously in neonates, particularly those with hyperbilirubinemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma ammonia and amino acids",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assists in lowering serum ammonia levels by activation of a nonurea cycle pathway (the benzoate-hippurate pathway); ammonia in the presence of benzoate will conjugate with glycine to form hippurate which is excreted by the kidney",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 0.75-7.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Clearance is largely attributable to metabolism with urinary excretion of hippurate, the major metabolite",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used to treat urea cycle enzyme deficiency in combination with arginine; a maximum of 1 mole nitrogen is removed for every 1 mole of benzoate administered",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Batshaw ML, &ldquo;Hyperammonemia,&rdquo;",
"      <i>",
"       Curr Probl Pediatr",
"      </i>",
"      , 1984, 14(11):1-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/6/32866/abstract-text/6510017 /pubmed\" id=\"6510017 \" target=\"_blank\">",
"        6510017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Batshaw ML and Brusilow SW, &ldquo;Treatment of Hyperammonemic Coma Caused by Inborn Errors of Urea Synthesis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1980, 97(6):893-900.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/6/32866/abstract-text/7441417/pubmed\" id=\"7441417\" target=\"_blank\">",
"        7441417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):S46-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/6/32866/abstract-text/11148549/pubmed\" id=\"11148549\" target=\"_blank\">",
"        11148549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Enns GM, Berry SA, Berry GT, et al, \"Survival After Treatment With Phenylacetate and Benzoate for Urea-Cycle Disorders,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(22):2282-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/6/32866/abstract-text/17538087/pubmed\" id=\"17538087\" target=\"_blank\">",
"        17538087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green TP, Marchessault RP, and Freese DK, &ldquo;Disposition of Sodium Benzoate in Newborn Infants With Hyperammonemia,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1983, 102(5):785-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/6/32866/abstract-text/6842341/pubmed\" id=\"6842341\" target=\"_blank\">",
"        6842341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maestri NE, Hauser ER, Bartholomew D, et al, &ldquo;Prospective Treatment of Urea Cycle Disorders,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 119(6):923-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/6/32866/abstract-text/1720458/pubmed\" id=\"1720458\" target=\"_blank\">",
"        1720458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Summar M, &ldquo;Current Strategies for the Management of Neonatal Urea Cycle Disorders,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):S30-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/6/32866/abstract-text/11148547 /pubmed\" id=\"11148547 \" target=\"_blank\">",
"        11148547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12794 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32866=[""].join("\n");
var outline_f32_6_32866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062157\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445041\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062154\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247197\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062160\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062159\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14198760\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062153\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300050\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222963\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062156\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062152\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062162\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062163\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12794\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12794|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_6_32867="NASPGHN evaluation CVS";
var content_f32_6_32867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Evaluation of cyclic vomiting pattern in children older than 2 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 762px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May not need metabolic evaluation.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32867=[""].join("\n");
var outline_f32_6_32867=null;
var title_f32_6_32868="Exstrophy Bryants traction";
var content_f32_6_32868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Postoperative use of  Bryants traction in patient with bladder exstrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Newborn stabilized in modified Bryant's traction following complete primary repair of bladder exstrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Joseph Borer.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32868=[""].join("\n");
var outline_f32_6_32868=null;
var title_f32_6_32869="Eprosartan and hydrochlorothiazide: Patient drug information";
var content_f32_6_32869=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Eprosartan and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/38/12903?source=see_link\">",
"     see \"Eprosartan and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Teveten&reg; HCT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Teveten&reg; HCT;",
"     </li>",
"     <li>",
"      Teveten&reg; Plus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eprosartan, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703719",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a block in the kidneys' arteries or other kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11175 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32869=[""].join("\n");
var outline_f32_6_32869=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165990\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165991\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021894\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021896\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021895\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021900\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021901\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021903\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021898\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021899\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021904\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021905\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/38/12903?source=related_link\">",
"      Eprosartan and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_6_32870="Cervical length in a curved cervix";
var content_f32_6_32870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Cervical length in a curved cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Evaluation of cervical length in a patient with a curved cervix. If the widest distance (A, red arrow) between the yellow lines is greater than 5 mm, use the sum of B and C as the best measurement of cervical length. If less than or equal to 5 mm, use D as the best measurement of cervical length.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32870=[""].join("\n");
var outline_f32_6_32870=null;
var title_f32_6_32871="Pathogenesis of Brucella";
var content_f32_6_32871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Pathogenesis of Brucella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing is a schematic representation of the major events in the pathogenesis of brucellosis and the host immune response. (1) Entry of brucella into the host, phagocytosis by macrophages and processing of brucella antigen. (2) Stimulation of T-lymphocytes to produce IFN-gamma. (3) Induction by IFN-gamma of direct activity of T-lymphocytes and macrophage induction against brucella. (4) Induction by INF-gamma of natural killer cells to kill brucella and induction of macrophage killing. (5) Inhibition of TNF-alpha production resulting in reduced killing by natural killer cells and macrophages. (6) Release of incompletely killed brucella to infect other cells. (7) Production of antibodies by B-lymphocytes. Important for diagnostic purposes but not for control of the disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32871=[""].join("\n");
var outline_f32_6_32871=null;
var title_f32_6_32872="Brain arteriovenous malformations";
var content_f32_6_32872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Brain arteriovenous malformations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32872/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32872/contributors\">",
"     Robert J Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32872/contributors\">",
"     Christopher S Ogilvy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32872/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32872/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32872/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32872/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32872/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/6/32872/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous malformations (AVMs) are the most dangerous congenital vascular malformations. They have become the focus of scientific study leading to technological advances that have permitted these high-flow lesions to be treated, often with a multidisciplinary approach utilizing surgical, endovascular, and radiosurgical techniques.",
"   </p>",
"   <p>",
"    This topic review will discuss brain AVMs. Three other general subtypes of congenital vascular malformations have been described: developmental venous anomalies, capillary telangiectasias, and cavernous malformations. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY, PATHOGENESIS, AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain AVMs occur in about 0.1 percent of the population, one-tenth the incidence of intracranial aneurysms. Supratentorial lesions account for 90 percent of brain AVMs; the remainder are in the posterior fossa. Brain AVMs account for 1 to 2 percent of all strokes, 3 percent of strokes in young adults, and 9 percent of subarachnoid hemorrhages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain AVMs are considered sporadic congenital developmental vascular lesions, but their pathogenesis is not well understood. Rare cases of familial brain AVMs have been reported but it is unclear if these are coincidental or indicate true familial occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/2\">",
"     2",
"    </a>",
"    ]. However, genetic variation may influence brain AVM development and clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a higher prevalence of vascular malformations associated with hereditary hemorrhagic telangiectasia (HHT; Osler-Weber-Rendu syndrome). Patients with HHT may have cerebral or spinal cord involvement with telangiectasias, brain AVMs, aneurysms, or cavernous malformations. The presence of more than one brain AVM, otherwise uncommon, is highly predictive of HHT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The angioarchitecture of brain AVMs is direct arterial to venous connections without an intervening capillary network. Gliotic brain is usually admixed with the vascular tangle, and calcification may be seen in the nidus and surrounding brain. This high-flow arteriovenous communication potentiates a variety of flow-related phenomena such as the development of afferent and efferent pedicle aneurysms and arterialization of the venous limb. Aneurysms can be a source of bleeding in patients with brain AVMs and are thought to worsen their prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The size of brain AVMs varies widely. There also are a variable number and location of arterial feeders and draining veins that impact upon prognosis and treatment.",
"   </p>",
"   <p>",
"    Regional brain perfusion is compromised due to the brain AVM \"stealing\" flow from normal surrounding parenchyma. As a result, histopathological studies demonstrate areas of chronic ischemia and gliosis in the region of the malformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain AVMs usually present between the ages of 10 and 40. The clinical presentation typically falls into one of four categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      intracranial hemorrhage (41 to 79 percent)",
"     </li>",
"     <li>",
"      seizure (11 to 33 percent)",
"     </li>",
"     <li>",
"      headache",
"     </li>",
"     <li>",
"      focal neurologic deficit",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children are more likely to present with hemorrhage than adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/8\">",
"     8",
"    </a>",
"    ]. The size, location, and other vascular features of the AVM influence the clinical presentation. Patients with superficial-draining AVMs are more likely to present with seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92720247\">",
"    <span class=\"h1\">",
"     HEMORRHAGE RISK AFTER PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large databanks that collect information prospectively, the Columbia AVM databank [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] and the Toronto Western Hospital AVM databank [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/12\">",
"     12",
"    </a>",
"    ] report an average annual rate of hemorrhage in patients with untreated brain AVMs ranging from 2.8 to 4.6.",
"   </p>",
"   <p>",
"    Hemorrhage rates vary according to identified risk factors. Hemorrhage as the initial clinical presentation was the strongest predictor for subsequent hemorrhage in patients with untreated brain AVMs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Clinically silent hemorrhage, seen on neuroimaging, is also a risk factor for subsequent hemorrhage according to another series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/13\">",
"     13",
"    </a>",
"    ]. Other independent predictors of subsequent hemorrhage in the Columbia databank were increasing age, exclusive deep venous drainage, and deep brain location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In the Toronto study, associated aneurysms and deep venous drainage showed a trend toward increased hemorrhage risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/12\">",
"     12",
"    </a>",
"    ]. In the Columbia databank, patients whose AVMs lacked hemorrhage at initial presentation, deep venous drainage, and deep brain location had an annual hemorrhage rate of 0.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, those with all three risk factors had an annual hemorrhage rate as high as 34.4 percent. Among 241 patients with untreated AVMs in the Columbia databank who initially presented with hemorrhage, a recurrent AVM hemorrhage occurred in 12 percent over an average 1.8 years of follow-up, yielding a crude rebleeding rate of 7 percent annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In earlier retrospective studies, the average annual mortality in patients with untreated brain AVMs ranged from 0.7 to 1.0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Children were not at higher risk of subsequent ICH after initial hemorrhage when compared with adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain AVMs are typically first discovered on cross-sectional imaging (CT or MRI), although angiography is required to plan therapy. A combination of MRI and angiography also is often used to assess the success of surgical, endovascular, or radiosurgical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow voids may be identified on CT with contrast administration in and around the region of the nidus of the brain AVM. CT characteristically demonstrates intraparenchymal hemorrhage without significant edema in patients who present with hemorrhage. However, compression of the nidus by the hematoma often precludes CT diagnosis of brain AVM in the setting of acute intracerebral hemorrhage; more sensitive techniques such as MRI or angiography are required in such cases. The sensitivity of CT to identify brain AVMs in the acute setting may be improved by CT angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is very sensitive for delineating the location of the brain AVM nidus and often an associated draining vein. It also has unique sensitivity in demonstrating remote bleeding related to these lesions. Dark flow voids are appreciated on T1 and T2-weighted studies (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53992 \" href=\"mobipreview.htm?33/37/34384\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    MRI also is particularly valuable in following patients after treatment. After radiosurgery, for example, the regression of the nidal volume can be accurately measured and followed. In addition, surrounding tissue that is subjected to the radiation field can be accurately monitored for post-therapy edema or, in some cases, radiation necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography is the gold standard for the diagnosis, treatment planning, and follow-up after treatment of brain AVMs (",
"    <a class=\"graphic graphic_picture graphicRef75190 \" href=\"mobipreview.htm?15/59/16304\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62349 \" href=\"mobipreview.htm?38/1/38943\">",
"     picture 2",
"    </a>",
"    ). Anatomical and physiological information such as the nidus configuration, its relationship to surrounding vessels, and localization of the draining or efferent portion of the brain AVM are readily obtained with this technique. Contrast transit times provide additional useful information regarding the flow state of the lesion; this is critical for endovascular treatment planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of variables are factored into the decision to treat AVMs and the therapy chosen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/16\">",
"     16",
"    </a>",
"    ]. Surgery is the mainstay of treatment; radiosurgery is a useful option in lesions deemed at high risk for surgical therapy, and endovascular embolization has become a useful adjunct to these techniques. An important but still unsettled issue concerns the long-term benefit of treatment for unruptured AVMs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Is treatment of unruptured AVMs beneficial?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the outcome of AVM treatment comes largely from case series and early reports from uncontrolled population-based studies. There is no evidence from randomized clinical trials to guide treatment decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although published only in abstract form, a preliminary analysis of a large AVM database suggested that interventional treatment of unruptured AVMs was associated with a worse outcome than no treatment, as shown by increased rates of subsequent hemorrhage and clinical impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, a prospective population-based registry from Scotland compared adults who received interventional AVM treatment (n = 63) with those who did not (n = 51) and reported that it was associated with worse short-term (three years) functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/20\">",
"     20",
"    </a>",
"    ]. A systematic review and meta-analysis of observational studies concluded that all available treatments were associated with considerable risks, including a 5.1 to 7.4 percent median rate of permanent neurologic complications or death, and incomplete efficacy of 13 to 96 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of these population-based reports must be interpreted cautiously, as they are nonrandomized and subject to bias in the selection of patients who are treated or not treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/22\">",
"     22",
"    </a>",
"    ]. As an example, patients in the Scottish study who received AVM treatment were on average younger, more likely to present with seizure, and less likely to have medical comorbidities at baseline than patients who were not treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, these reports, and the absence of definitive data, has led to controversy regarding the utility of treatment for unruptured AVMs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. An ongoing randomized controlled trial is comparing medical management of unruptured brain AVMs with invasive treatment, including any combination of surgery, radiosurgery, or endovascular embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Who should be treated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age is an important factor in the decision to treat brain AVMs, since the annual risk of hemorrhage and associated morbidity and mortality statistics are weighed against life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, children and young adults are usually recommended for therapy, while older individuals with shorter life expectancies may be managed more conservatively.",
"   </p>",
"   <p>",
"    Another important factor in recommending therapy is an assessment of surgical risk. One group used anatomic considerations to construct a classification system (now referred to as the Spetzler-Martin grading scale) that takes into account the lesion size, location, and venous drainage pattern (",
"    <a class=\"graphic graphic_table graphicRef71261 \" href=\"mobipreview.htm?31/22/32107\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients are graded in accordance with these variables; outcomes have consistently been directly related to these factors. High-grade lesions are those of larger size in eloquent brain areas (eg, areas of critical cortical function, deep nuclei, brainstem) with deep venous drainage patterns that make them the most difficult to safely resect. Female gender may also increase surgical risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A formula has been devised that considers both patient age and the annual risk of hemorrhage to give an estimate of cumulative hemorrhage risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifetime risk of hemorrhage = 1 - (risk of no hemorrhage) ^ N",
"      <br/>",
"      <br/>",
"      where N is the expected years of life remaining.",
"      <br/>",
"      <br/>",
"      The risk of no hemorrhage can be expressed as 1 - P, where P is the annual probability of hemorrhage.",
"      <br/>",
"      <br/>",
"      Thus the formula can be expressed as 1 - (1 - P) ^ N",
"      <br/>",
"      <br/>",
"      As an example, a 60-year-old woman with a newly diagnosed brain AVM and no other contributing comorbid conditions would expect to live approximately 20 years. If the annual risk of AVM hemorrhage is 3 percent, the formula gives a cumulative risk of hemorrhage over her expected life span of 46 percent. This compares with an overall risk of treatment morbidity and mortality of approximately 5 percent, thereby justifying treatment. This calculation only serves as a rough guideline to assist in clinical decision making and is based upon cumulative data rather than an individual patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An easy-to-use, simpler approximation of the above formula has also been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifetime risk of hemorrhage = 105 - patient age in years",
"      <br/>",
"      <br/>",
"      Thus, for the same 60-year-old patient, the simple formula gives a lifetime hemorrhage risk of 45 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Risk during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the available data suggest that the risk of hemorrhage from an brain AVM is not increased during pregnancy, but the issue is controversial, and no definitive data exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/32\">",
"     32",
"    </a>",
"    ]. One of the better studies was a retrospective analysis of 451 women with a brain AVM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/33\">",
"     33",
"    </a>",
"    ]. The AVM hemorrhage rate in pregnant women in this population was not significantly different compared with the rate for nonpregnant women (3.5 versus 3.1 percent per person-year).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactically focused high energy beams of photons or protons to a defined volume containing the brain AVM nidus induces progressive thrombosis of properly selected lesions via fibrointimal hyperplasia and subsequent luminal obliteration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The time course of these events is usually one to three years, and the time between treatment and obliteration is referred to as the latency period. Once the lesion is completely obliterated, the hemorrhage risk from the brain AVM is very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], but not totally eliminated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Incomplete lesion obliteration, hypertension, and prior hemorrhage are risk factors for late bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence concerning the hemorrhage risk during the latency period between treatment and obliteration is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/39\">",
"     39",
"    </a>",
"    ]. This is an important consideration, particularly for lesions with an aggressive clinical course, such as those presenting with a previous hemorrhage and afferent pedicle or intranidal aneurysms. There are no randomized controlled trials of radiosurgery for brain AVMs, and none are likely to be performed as the benefit of radiosurgery for radiographic obliteration of brain AVMs is widely accepted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/35\">",
"     35",
"    </a>",
"    ]. Existing studies are generally limited by retrospective and observational design.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Earlier studies had suggested that the bleeding rate during the latency period compared with an untreated brain AVM was unchanged [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/40,41\">",
"       40,41",
"      </a>",
"      ], was decreased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/42,43\">",
"       42,43",
"      </a>",
"      ], or was increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. Most of these studies analyzed the risk of hemorrhage by comparing selected patients who had radiosurgery with those who did not have radiosurgery.",
"     </li>",
"     <li>",
"      Stronger evidence supporting a reduced brain AVM hemorrhage rate in the latency period comes from a subsequent study that analyzed changes in the rate of hemorrhage relative to the timing of radiosurgery in a cohort of 500 consecutive patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/36\">",
"       36",
"      </a>",
"      ]. The risk of hemorrhage declined by 54 percent during the latency period (hazard ratio (HR) 0.46, 95% CI 0.26-0.80) and by 88 percent after obliteration (HR 0.12, 95% CI 0.05-0.29). The risk reduction was greater among patients who presented with hemorrhage than those who presented without hemorrhage. Another study in 657 patients had similar findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Successful brain AVM obliteration with radiosurgery depends upon lesion size and dose of radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete cure is considerably higher with smaller lesions; an overall 80 percent obliteration rate by three years occurs with lesions that are 3 cm or smaller [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/46,48-51\">",
"       46,48-51",
"      </a>",
"      ]. Larger lesions have reported obliteration rates of 30 to 70 percent at three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/48,50,52\">",
"       48,50,52",
"      </a>",
"      ]. Brain AVMs with a diffuse nidus or associated neovascularity were less likely to achieve a radiographic cure in one clinical series of 248 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/53\">",
"       53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Despite the lower initial success rates for angiographic obliteration seen with larger brain AVMs (&gt;3 cm), some amount of lesion volume reduction (mean 66 percent) typically occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. Retreatment is effective for complete obliteration in about 60 to 80 percent of patients with residual brain AVMs, depending on the size and other factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/54,56\">",
"       54,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The success rate of radiographic brain AVM obliteration varies with the amount of radiation delivered to the margin of the lesion. Doses of 16, 18, and 20 Gy are associated with obliteration rates of about 70, 80, and 90 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/55,57,58\">",
"       55,57,58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although radiosurgery for brain AVM is usually performed to reduce the lifetime risk of bleeding, improved seizure control may be another benefit for some patients. In a study of 65 patients who had seizures before treatment with stereotactic radiosurgery for brain AVM, 25 (51 percent) were free of seizures and auras three years after treatment, including the 13 patients who had a single seizure only before treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/59\">",
"     59",
"    </a>",
"    ]. Of the 23 patients with disabling seizures before treatment, 11 (61.1 percent) had an excellent outcome (defined as seizure-free or nondisabling seizures) at three-year follow-up. Better outcomes were associated with a low frequency of seizures before treatment and smaller size brain AVM. The results of this study are limited by retrospective design and absence of a control group. In another retrospective study, 77 percent of 86 patients with a history of seizure and AVM were seizure free after a mean follow-up of 90 months after radiosurgery; 58 percent were also medication-free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/60\">",
"     60",
"    </a>",
"    ]. Rates of seizure remission were higher among those whose AVM was completely obliterated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications after radiosurgery include radiation necrosis with new neurologic deficits and seizures. In a multinational study that included 1255 patients undergoing radiosurgery for cerebral AVMs, therapy-related complications developed in 102 (8 percent) and included radiographic parenchymal lesions, cranial nerve deficits, seizures, headaches, and cyst formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/61\">",
"     61",
"    </a>",
"    ]. Symptoms were disabling in 21, fatal in two, and resolved completely in 42 (41 percent). The risk of radiation necrosis with permanent neurologic deficit is 1 to 3 percent in most reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/48,50,55\">",
"     48,50,55",
"    </a>",
"    ]. In another case series, 10 of 75 patients who had not had seizures and were not on antiepileptic drugs before radiosurgery had provoked seizures after radiosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the success rate and incidence of complications are related to the brain AVM location and the volume treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/51,62\">",
"     51,62",
"    </a>",
"    ]. Thalamic, basal ganglionic, and brainstem locations are particularly prone to development of deficits after radiosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The risk of complications is also related to the radiation dose directed to the surrounding tissue.",
"   </p>",
"   <p>",
"    The increased risk of complications in large brain AVMs that require larger treatment volumes was illustrated in a series of 73 patients, in whom one-half of the brain AVMs were &gt;3 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/64\">",
"     64",
"    </a>",
"    ]. The incidence of post-treatment imaging abnormalities and clinical complications rose with increasing treatment volume. In patients whose treatment volumes were &gt;14 mL and who received a dose &ge;16 Gy, the incidence of post-treatment MRI abnormalities was 72 percent, and 22 percent required resection for radiation necrosis. The rate of post-treatment hemorrhage was also higher for treatment volumes &ge;14 mL (7.5 versus 2.7 percent per person-year).",
"   </p>",
"   <p>",
"    Repeated radiosurgery is also associated with increased complications; but the rate is not clearly prohibitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/56,65\">",
"     56,65",
"    </a>",
"    ]. In one series of 15 patients who underwent two radiosurgeries with a mean dose per session of 18 Gy and 21 Gy, three (20 percent) had permanent radiation-induced complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/65\">",
"     65",
"    </a>",
"    ]. No rebleeding occurred over 137 patient-years of follow-up.",
"   </p>",
"   <p>",
"    In contrast to standard fractionation cranial irradiation, radiosurgery does not appear to impact on cognitive function. One study of 10 patients found no effect of radiosurgical treatment of brain AVMs upon neuropsychological performance 11 months after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endovascular techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite initial optimism that embolic agents such as microparticles and cyanoacrylates could cure brain AVMs, less than 5 percent of lesions are cured by this approach alone. In addition, flow studies have demonstrated that partial embolization may increase the pedicle pressure and the risk of hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, embolization is an effective adjunct to radiosurgery and surgery. Embolization prior to radiosurgery is employed to reduce the nidus size of large brain AVMs to less than 10 cm3, as these large AVMs have a lower cure rate with radiosurgery alone (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Stereotactic radiosurgery'",
"    </a>",
"    above). Embolization prior to surgery is employed to reduce blood loss and to occlude vessels that may be difficult to control during surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/32\">",
"     32",
"    </a>",
"    ]. Furthermore, endovascular treatment appears to be associated with a relatively low risk of disabling treatment complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meticulous analysis of angiographic information (size, eloquent location, deep versus superficial venous drainage, vascular",
"    <span class=\"nowrap\">",
"     anatomy/number",
"    </span>",
"    of feeders) determines the suitability for embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/69\">",
"     69",
"    </a>",
"    ]. Generally, only afferent pedicles to the nidus are embolized in an attempt to avoid occlusion of branches irrigating normal brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     ASA guideline recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the management of AVMs were published by the American Stroke Association (ASA) in 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/35\">",
"     35",
"    </a>",
"    ]. Of note, these recommendations were made before the publication of population-based studies that suggest no benefit for interventional treatment of unruptured AVMs. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Is treatment of unruptured AVMs beneficial?'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The ASA guideline makes the following recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical extirpation should be considered the primary mode of therapy for low-grade (I and II) lesions based upon the Spetzler-Martin grading scale (",
"      <a class=\"graphic graphic_table graphicRef71261 \" href=\"mobipreview.htm?31/22/32107\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/35\">",
"       35",
"      </a>",
"      ]. Radiosurgery should be considered for small lesions when surgery may be associated with increased risk based on anatomic location or feeding vessel anatomy.",
"     </li>",
"     <li>",
"      Combined treatment with endovascular embolization followed by surgery may be used in patients with grade III lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Invasive treatment of grade IV and V lesions is associated with a high risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/35\">",
"       35",
"      </a>",
"      ], and such AVMs are generally managed conservatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of aneurysms associated with AVMs varies depending on aneurysm location and diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For feeding artery aneurysms &gt;7 mm diameter, microsurgical clipping or endovascular coiling is suggested prior to treatment of the AVM.",
"     </li>",
"     <li>",
"      For aneurysms located within the AVM (intranidal), treatment occurs in conjunction with treatment of the AVM itself.",
"     </li>",
"     <li>",
"      For aneurysms located in an artery that does not feed the AVM, management is similar to that of intracranial aneurysms in patients without a brain AVM. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=see_link\">",
"       \"Unruptured intracranial aneurysms\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3474402\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual with AVMs may present with or later develop epilepsy. In one series, the 5-year seizure risk for AVMs that were discovered incidentally was 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/70\">",
"     70",
"    </a>",
"    ]. In contrast, patients who presented with ICH or focal neurologic deficits had a 23 percent 5-year risk of seizures.",
"   </p>",
"   <p>",
"    Antiepileptic drug (AED) therapy is generally successful in preventing recurrent seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32872/abstract/70\">",
"     70",
"    </a>",
"    ]. However, prophylactic AED therapy to prevent a first seizure occurrence is generally not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/42/26274?source=see_link\">",
"       \"Patient information: Arteriovenous malformations in the brain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain arteriovenous malformations (AVMs) are considered to be sporadic congenital developmental vascular lesions. They occur in about 0.1 percent of the population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain AVMs usually present between the ages of 10 and 40 years with either intracranial hemorrhage, seizure, headache, and focal neurologic deficit. Hemorrhage is the most common presentation, particularly in children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Annual hemorrhage rates from brain AVMs are between 3 to 5 percent. After an initial hemorrhage, annual hemorrhage rates are approximately 8 percent. (See",
"      <a class=\"local\" href=\"#H92720247\">",
"       'Hemorrhage risk after presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain AVMs can be detected on computed tomography or magnetic resonance imaging (MRI). MRI is more sensitive, particularly in the setting of an acute intracerebral hemorrhage. Angiography is the gold standard for the diagnosis, treatment planning, and follow-up after treatment of brain AVMs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of variables are factored into the decision to treat AVMs and the therapy chosen. Surgery is the mainstay of treatment; radiosurgery is a useful option in lesions deemed at high risk for surgical therapy, and endovascular embolization has become a useful adjunct to these techniques. Important considerations in the choice of treatment are the patient's age, lesion size and location, and prior history of intracerebral hemorrhage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'ASA guideline recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/1\">",
"      Al-Shahi R, Warlow C. A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults. Brain 2001; 124:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/2\">",
"      van Beijnum J, van der Worp HB, Schippers HM, et al. Familial occurrence of brain arteriovenous malformations: a systematic review. J Neurol Neurosurg Psychiatry 2007; 78:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/3\">",
"      Hashimoto T, Lawton MT, Wen G, et al. Gene microarray analysis of human brain arteriovenous malformations. Neurosurgery 2004; 54:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/4\">",
"      Pawlikowska L, Tran MN, Achrol AS, et al. Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke 2004; 35:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/5\">",
"      Bharatha A, Faughnan ME, Kim H, et al. Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment. Stroke 2012; 43:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/6\">",
"      Perata HJ, Tomsick TA, Tew JM Jr. Feeding artery pedicle aneurysms: association with parenchymal hemorrhage and arteriovenous malformation in the brain. J Neurosurg 1994; 80:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/7\">",
"      Garcin B, Houdart E, Porcher R, et al. Epileptic seizures at initial presentation in patients with brain arteriovenous malformation. Neurology 2012; 78:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/8\">",
"      Fullerton HJ, Achrol AS, Johnston SC, et al. Long-term hemorrhage risk in children versus adults with brain arteriovenous malformations. Stroke 2005; 36:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/9\">",
"      Khaw AV, Mohr JP, Sciacca RR, et al. Association of infratentorial brain arteriovenous malformations with hemorrhage at initial presentation. Stroke 2004; 35:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/10\">",
"      Stapf C, Mast H, Sciacca RR, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology 2006; 66:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/11\">",
"      Choi JH, Mast H, Sciacca RR, et al. Clinical outcome after first and recurrent hemorrhage in patients with untreated brain arteriovenous malformation. Stroke 2006; 37:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/12\">",
"      da Costa L, Wallace MC, Ter Brugge KG, et al. The natural history and predictive features of hemorrhage from brain arteriovenous malformations. Stroke 2009; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/13\">",
"      Guo Y, Saunders T, Su H, et al. Silent intralesional microhemorrhage as a risk factor for brain arteriovenous malformation rupture. Stroke 2012; 43:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/14\">",
"      Brown RD Jr, Wiebers DO, Forbes G, et al. The natural history of unruptured intracranial arteriovenous malformations. J Neurosurg 1988; 68:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/15\">",
"      Ondra SL, Troupp H, George ED, Schwab K. The natural history of symptomatic arteriovenous malformations of the brain: a 24-year follow-up assessment. J Neurosurg 1990; 73:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/16\">",
"      Friedlander RM. Clinical practice. Arteriovenous malformations of the brain. N Engl J Med 2007; 356:2704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/17\">",
"      Al-Shahi R, Warlow C. Arteriovenous malformations of the brain: ready to randomise? J Neurol Neurosurg Psychiatry 2005; 76:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/18\">",
"      Al-Shahi R, Warlow CP. Interventions for treating brain arteriovenous malformations in adults. Cochrane Database Syst Rev 2006; :CD003436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/19\">",
"      Mohr JP, Stapf C, Sciacca RR, et al. Treatment outcome versus natural history risk in patients with unruptured brain arteriovenous malformation [abstract]. Neurology 2004; 62 (Suppl 5):A101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/20\">",
"      Wedderburn CJ, van Beijnum J, Bhattacharya JJ, et al. Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study. Lancet Neurol 2008; 7:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/21\">",
"      van Beijnum J, van der Worp HB, Buis DR, et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA 2011; 306:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/22\">",
"      Brown RD Jr. Unruptured brain AVMs: to treat or not to treat. Lancet Neurol 2008; 7:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/23\">",
"      Stapf C, Mohr JP. Unruptured brain arteriovenous malformations should be treated conservatively: yes. Stroke 2007; 38:3308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/24\">",
"      Cockroft KM. Unruptured brain arteriovenous malformations should be treated conservatively: no. Stroke 2007; 38:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/25\">",
"      Davis SM, Donnan GA. Unruptured brain arteriovenous malformations: another asymptomatic conundrum. Stroke 2007; 38:3312.",
"     </a>",
"    </li>",
"    <li>",
"     A randomized trial of unruptured brain AVMs (ARUBA). NCT00389181. Available at file://clinicaltrials.gov/ct/show/NCT00389181?order=2 (Accessed on May 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/27\">",
"      Tamaki N, Ehara K, Lin TK, et al. Cerebral arteriovenous malformations: factors influencing the surgical difficulty and outcome. Neurosurgery 1991; 29:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/28\">",
"      Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg 1986; 65:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/29\">",
"      Hartmann A, Stapf C, Hofmeister C, et al. Determinants of neurological outcome after surgery for brain arteriovenous malformation. Stroke 2000; 31:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/30\">",
"      Kondziolka D, McLaughlin MR, Kestle JR. Simple risk predictions for arteriovenous malformation hemorrhage. Neurosurgery 1995; 37:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/31\">",
"      Brown RD Jr. Simple risk predictions for arteriovenous malformation hemorrhage. Neurosurgery 2000; 46:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/32\">",
"      Brown RD Jr, Flemming KD, Meyer FB, et al. Natural history, evaluation, and management of intracranial vascular malformations. Mayo Clin Proc 2005; 80:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/33\">",
"      Horton JC, Chambers WA, Lyons SL, et al. Pregnancy and the risk of hemorrhage from cerebral arteriovenous malformations. Neurosurgery 1990; 27:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/34\">",
"      Maruyama K, Kondziolka D, Niranjan A, et al. Stereotactic radiosurgery for brainstem arteriovenous malformations: factors affecting outcome. J Neurosurg 2004; 100:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/35\">",
"      Ogilvy CS, Stieg PE, Awad I, et al. AHA Scientific Statement: Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke 2001; 32:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/36\">",
"      Maruyama K, Kawahara N, Shin M, et al. The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med 2005; 352:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/37\">",
"      Sun DQ, Carson KA, Raza SM, et al. The radiosurgical treatment of arteriovenous malformations: obliteration, morbidities, and performance status. Int J Radiat Oncol Biol Phys 2011; 80:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/38\">",
"      Parkhutik V, Lago A, Tembl JI, et al. Postradiosurgery hemorrhage rates of arteriovenous malformations of the brain: influencing factors and evolution with time. Stroke 2012; 43:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/39\">",
"      Karlsson B, Lax I, S&ouml;derman M. Risk for hemorrhage during the 2-year latency period following gamma knife radiosurgery for arteriovenous malformations. Int J Radiat Oncol Biol Phys 2001; 49:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/40\">",
"      Pollock BE, Flickinger JC, Lunsford LD, et al. Hemorrhage risk after stereotactic radiosurgery of cerebral arteriovenous malformations. Neurosurgery 1996; 38:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/41\">",
"      Friedman WA, Blatt DL, Bova FJ, et al. The risk of hemorrhage after radiosurgery for arteriovenous malformations. J Neurosurg 1996; 84:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/42\">",
"      Levy RP, Fabrikant JI, Frankel KA, et al. Stereotactic heavy-charged-particle Bragg peak radiosurgery for the treatment of intracranial arteriovenous malformations in childhood and adolescence. Neurosurgery 1989; 24:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/43\">",
"      Karlsson B, Lindquist C, Steiner L. Effect of Gamma Knife surgery on the risk of rupture prior to AVM obliteration. Minim Invasive Neurosurg 1996; 39:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/44\">",
"      Steinberg GK, Fabrikant JI, Marks MP, et al. Stereotactic heavy-charged-particle Bragg-peak radiation for intracranial arteriovenous malformations. N Engl J Med 1990; 323:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/45\">",
"      Fabrikant JI, Levy RP, Steinberg GK, et al. Charged-particle radiosurgery for intracranial vascular malformations. Neurosurg Clin N Am 1992; 3:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/46\">",
"      Kurita H, Kawamoto S, Sasaki T, et al. Results of radiosurgery for brain stem arteriovenous malformations. J Neurol Neurosurg Psychiatry 2000; 68:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/47\">",
"      Yen CP, Sheehan JP, Schwyzer L, Schlesinger D. Hemorrhage risk of cerebral arteriovenous malformations before and during the latency period after GAMMA knife radiosurgery. Stroke 2011; 42:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/48\">",
"      Lunsford LD, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for arteriovenous malformations of the brain. J Neurosurg 1991; 75:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/49\">",
"      Ogilvy CS. Radiation therapy for arteriovenous malformations: a review. Neurosurgery 1990; 26:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/50\">",
"      Fabrikant JI, Levy RP, Steinberg GK, et al. Stereotactic charged-particle radiosurgery: clinical results of treatment of 1200 patients with intracranial arteriovenous malformations and pituitary disorders. Clin Neurosurg 1992; 38:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/51\">",
"      Skj&oslash;th-Rasmussen J, Roed H, Ohlhues L, et al. Complications following linear accelerator based stereotactic radiation for cerebral arteriovenous malformations. Int J Radiat Oncol Biol Phys 2010; 77:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/52\">",
"      Friedman WA, Bova FJ, Bollampally S, Bradshaw P. Analysis of factors predictive of success or complications in arteriovenous malformation radiosurgery. Neurosurgery 2003; 52:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/53\">",
"      Zipfel GJ, Bradshaw P, Bova FJ, Friedman WA. Do the morphological characteristics of arteriovenous malformations affect the results of radiosurgery? J Neurosurg 2004; 101:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/54\">",
"      Foote KD, Friedman WA, Ellis TL, et al. Salvage retreatment after failure of radiosurgery in patients with arteriovenous malformations. J Neurosurg 2003; 98:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/55\">",
"      Pollock BE, Meyer FB. Radiosurgery for arteriovenous malformations. J Neurosurg 2004; 101:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/56\">",
"      Hauswald H, Milker-Zabel S, Sterzing F, et al. Repeated linac-based radiosurgery in high-grade cerebral arteriovenous-malformations (AVM) Spetzler-Martin grade III to IV previously treated with radiosurgery. Radiother Oncol 2011; 98:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/57\">",
"      Flickinger JC, Pollock BE, Kondziolka D, Lunsford LD. A dose-response analysis of arteriovenous malformation obliteration after radiosurgery. Int J Radiat Oncol Biol Phys 1996; 36:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/58\">",
"      Karlsson B, Lindquist C, Steiner L. Prediction of obliteration after gamma knife surgery for cerebral arteriovenous malformations. Neurosurgery 1997; 40:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/59\">",
"      Sch&auml;uble B, Cascino GD, Pollock BE, et al. Seizure outcomes after stereotactic radiosurgery for cerebral arteriovenous malformations. Neurology 2004; 63:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/60\">",
"      Yang SY, Kim DG, Chung HT, Paek SH. Radiosurgery for unruptured cerebral arteriovenous malformations: long-term seizure outcome. Neurology 2012; 78:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/61\">",
"      Flickinger JC, Kondziolka D, Lunsford LD, et al. A multi-institutional analysis of complication outcomes after arteriovenous malformation radiosurgery. Int J Radiat Oncol Biol Phys 1999; 44:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/62\">",
"      Flickinger JC, Kondziolka D, Lunsford LD, et al. Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous Malformation Radiosurgery Study Group. Int J Radiat Oncol Biol Phys 2000; 46:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/63\">",
"      Pollock BE, Gorman DA, Brown PD. Radiosurgery for arteriovenous malformations of the basal ganglia, thalamus, and brainstem. J Neurosurg 2004; 100:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/64\">",
"      Miyawaki L, Dowd C, Wara W, et al. Five year results of LINAC radiosurgery for arteriovenous malformations: outcome for large AVMS. Int J Radiat Oncol Biol Phys 1999; 44:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/65\">",
"      Buis DR, Meijer OW, van den Berg R, et al. Clinical outcome after repeated radiosurgery for brain arteriovenous malformations. Radiother Oncol 2010; 95:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/66\">",
"      Blonder LX, Hodes JE, Ranseen JD, Schmitt FA. Short-term neuropsychological outcome following Gamma Knife radiosurgery for arteriovenous malformations: a preliminary report. Appl Neuropsychol 1999; 6:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/67\">",
"      Spetzler RF, Martin NA, Carter LP, et al. Surgical management of large AVM's by staged embolization and operative excision. J Neurosurg 1987; 67:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/68\">",
"      Hartmann A, Pile-Spellman J, Stapf C, et al. Risk of endovascular treatment of brain arteriovenous malformations. Stroke 2002; 33:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/69\">",
"      Starke RM, Komotar RJ, Otten ML, et al. Adjuvant embolization with N-butyl cyanoacrylate in the treatment of cerebral arteriovenous malformations: outcomes, complications, and predictors of neurologic deficits. Stroke 2009; 40:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32872/abstract/70\">",
"      Josephson CB, Leach JP, Duncan R, et al. Seizure risk from cavernous or arteriovenous malformations: prospective population-based study. Neurology 2011; 76:1548.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1087 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32872=[""].join("\n");
var outline_f32_6_32872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY, PATHOGENESIS, AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92720247\">",
"      HEMORRHAGE RISK AFTER PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Is treatment of unruptured AVMs beneficial?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Risk during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endovascular techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ASA guideline recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3474402\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1087|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/37/34384\" title=\"diagnostic image 1\">",
"      Dark flow void from AVM on MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1087|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/59/16304\" title=\"picture 1\">",
"      AVM pretreatment angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/1/38943\" title=\"picture 2\">",
"      AVM posttreatment angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1087|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/22/32107\" title=\"table 1\">",
"      Spetzler Martin grading scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/42/26274?source=related_link\">",
"      Patient information: Arteriovenous malformations in the brain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_6_32873="Overview of cancer survivorship care for primary care and oncology providers";
var content_f32_6_32873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of cancer survivorship care for primary care and oncology providers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32873/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32873/contributors\">",
"     Larissa Nekhlyudov, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32873/contributors\">",
"     Claire Snyder, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32873/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32873/contributors\">",
"     Patricia A Ganz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32873/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32873/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/6/32873/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11933956\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;cancer survivor&rdquo; has been used variably in the literature; most commonly, a cancer survivor refers to any person who has been diagnosed with cancer. Therefore, survivorship begins at the time of diagnosis and includes the periods of initial treatment with intent to cure, cancer-free survival, chronic or intermittent disease, and palliative care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are now over 13 million cancer survivors in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/2\">",
"     2",
"    </a>",
"    ] and close to 30 million survivors worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/3\">",
"     3",
"    </a>",
"    ]. This number is expected to grow due to improvements in cancer screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/4\">",
"     4",
"    </a>",
"    ], increases in life expectancy following definitive cancer treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/2,4\">",
"     2,4",
"    </a>",
"    ], and the aging of the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies report that cancer survivors often do not receive the appropriate oncology and primary care services, with evidence of overuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/6-9\">",
"     6-9",
"    </a>",
"    ] and underuse of services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/6,7,9-15\">",
"     6,7,9-15",
"    </a>",
"    ]. For cancer survivors who are no longer in active treatment, healthcare needs include surveillance for recurrence, screening for the development of secondary cancers, monitoring for the long-term and late physical and psychological effects of cancer and its treatment, management of comorbid medical conditions, as well as routine preventive and primary care. Unfortunately, there are few data available on how to best provide oncology and primary care in a coordinated and comprehensive fashion.",
"   </p>",
"   <p>",
"    In this topic, we provide an overview of cancer survivorship care and address ways to enhance the care for cancer survivors. For this review, we will concentrate on the care of patients who have completed treatment with curative intent. A discussion on the phases of cancer survivorship and topics on cancer survivorship for patients with a specific diagnosis are addressed elsewhere. (See",
"    <a class=\"local\" href=\"#H116772781\">",
"     'Cancer-specific information for survivors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11933963\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF CANCER SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of individuals diagnosed with cancer has increased dramatically from approximately 3 million in the 1970s to over 13 million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately 65 percent of cancer survivors were diagnosed within the past five years, 25 percent within the past 5 to 10 years, while the remainder has survived for over 10 years. Women comprise approximately 53 percent of the survivors.",
"   </p>",
"   <p>",
"    The most common cancer types among female survivors who achieve long-term remission include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Breast cancer (41 percent)",
"     </li>",
"     <li>",
"      Cancer of the uterine corpus (8 percent)",
"     </li>",
"     <li>",
"      Cancer of the colon or rectum (8 percent)",
"     </li>",
"     <li>",
"      Melanoma (7 percent)",
"     </li>",
"     <li>",
"      Thyroid cancer (6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among male survivors, the most common cancers include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/2\">",
"     2",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prostate cancer (43 percent)",
"     </li>",
"     <li>",
"      Cancer of the colon or rectum (9 percent)",
"     </li>",
"     <li>",
"      Melanoma (7 percent)",
"     </li>",
"     <li>",
"      Bladder cancer (7 percent)",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphomas (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most cancer survivors are older individuals; approximately 25 and 45 percent are aged 60 to 69 and 70 or older, respectively. Only five percent of survivors are younger than age 40, although an estimated 70,000 adolescents and young adults (ages 15 to 39) are diagnosed with cancer each year in the United States alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418030573\">",
"    <span class=\"h1\">",
"     GUIDELINES FOR POSTTREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transition from active treatment to posttreatment care is critical to long-term health. A committee established at the Institute of Medicine (IOM) to examine the range of medical and psychosocial issues faced by cancer survivors defined the following components of survivorship care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of recurrent and new cancers, and of other late effects.",
"     </li>",
"     <li>",
"      Surveillance",
"      <strong>",
"      </strong>",
"      for cancer spread, recurrence, or second cancers.",
"     </li>",
"     <li>",
"      Assessment of medical and psychosocial late effects.",
"     </li>",
"     <li>",
"      Intervention",
"      <strong>",
"      </strong>",
"      for consequences of cancer and its treatment, for example: medical problems such as lymphedema and sexual dysfunction; symptoms, including pain and fatigue; psychological distress experienced by cancer survivors and their caregivers.",
"     </li>",
"     <li>",
"      Evaluation of concerns related to employment, insurance, and disability.",
"     </li>",
"     <li>",
"      Coordination",
"      <strong>",
"      </strong>",
"      between specialists and primary care providers to ensure that all of the survivor&rsquo;s health needs are met.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11933970\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11933979\">",
"    <span class=\"h2\">",
"     Risk of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following treatment of a primary cancer, survivors are at risk for recurrence. Recurrences may occur at the initial site (ie, a locoregional recurrence) or in a different location (ie, metastatic disease). The timing and patterns of recurrence, particularly of distant disease, vary by cancer type and stage at diagnosis.",
"   </p>",
"   <p>",
"    In most instances, testing to evaluate for recurrent or metastatic disease should not be performed in otherwise asymptomatic cancer survivors. Unfortunately, the data indicate that overuse of imaging and laboratory testing, is common, even though not recommended in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Further, in surveys of physicians, data have shown that for those malignancies with existing guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], both oncologists and primary care providers often endorse testing that is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11933986\">",
"    <span class=\"h2\">",
"     Cancer surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to recurrences of primary malignancies, cancer survivors are at a higher risk for secondary malignancies as a result of treatment with either chemotherapy or RT. However, the risk may also be increased due to lifestyle factors, such as smoking or alcohol use.",
"   </p>",
"   <p>",
"    Chemotherapy-related leukemias can occur within two to five years following treatment with alkylating agents, topoisomerase inhibitors, and platinum agents, with risk typically declining after 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Alkylating agents can also increase risk of a new solid tumor, including lung, gastrointestinal, bladder, and breast cancers, as well as sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/21\">",
"     21",
"    </a>",
"    ]. Radiation-induced secondary malignancies are typically associated with a longer latency period of at least 5 to 10 years after treatment and are associated with the cumulative dose, field of radiation, and age at treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition, cancer survivors may be at higher risk for second cancers related to lifestyle habits, such as smoking, as well as genetic factors, such as mutations in the retinoblastoma gene (Rb) and TP53 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients treated for Hodgkin lymphoma and oral cavity malignancies may be at the highest risk for secondary malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/22-24\">",
"     22-24",
"    </a>",
"    ], likely related to treatment and lifestyle factors, respectively.",
"   </p>",
"   <p>",
"    Studies show that surveillance care among cancer survivors is suboptimal, which may be due to many factors, including lack of available evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consensus based guidelines. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 797 breast cancer survivors, the use of mammography in the first year after treatment was 80 percent, but this significantly declined over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/25\">",
"       25",
"      </a>",
"      ]. Women seen by a primary care physician or gynecologist were more likely to undergo mammography in that year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/6-8,15,25,26\">",
"       6-8,15,25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a separate study of colorectal cancer survivors, only 17 percent of colorectal cancer survivors received care in line with recommendations from the American Society of Clinical Oncology and the National Comprehensive Cancer Network [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among female survivors of childhood cancer treated with chest radiation, another study found that 64 percent of those aged 25 through 39 years, and 24 percent of those aged 40 through 50 years had not had mammography screening for breast cancer within the previous two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/27\">",
"       27",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418032179\">",
"    <span class=\"h2\">",
"     Monitoring for long term and late effects of cancer and its treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to secondary cancers, cancer survivors are at risk for other conditions related to both their disease and its treatment, which are of increasing importance as survival rates improve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/1,2,20,21,28-35\">",
"     1,2,20,21,28-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late effects of treatment arise months to years after cancer treatment is over, while long-term effects arise during cancer treatment and persist even after treatment has ended. While late effects for survivors of pediatric cancers have had greater emphasis in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/28,36-38\">",
"     28,36-38",
"    </a>",
"    ], there have been limited data about these outcomes for survivors diagnosed as adults. Fortunately, a more concerted effort to evaluate this is underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/39\">",
"     39",
"    </a>",
"    ].",
"    <em>",
"    </em>",
"   </p>",
"   <p>",
"    Among the more commonly reported late and long-term effects of chemotherapy are cardiomyopathy, peripheral neuropathy, and for women, issues related to premature menopause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/2,20,28-35\">",
"     2,20,28-35",
"    </a>",
"    ]. While data are lacking about the potential benefits of early recognition and intervention, earlier identification could improve long-term function, reduce debilitating symptoms, and potentially reduce mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Therefore, without appropriate awareness of late effects by patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    providers, symptoms may either be discounted",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    attributed to other causes, leading to misinformed evaluation and possibly delayed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inappropriate treatment.",
"   </p>",
"   <p>",
"    For these reasons, it is important that in the transition of patients from oncology to primary care settings, primary care providers be informed about the potential late and long term effects of cancer treatment so that they may be better prepared to recognize and address these among the cancer survivors in their care (",
"    <a class=\"graphic graphic_table graphicRef51130 \" href=\"mobipreview.htm?23/12/23757\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H418030689\">",
"     'Coordination of care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418032811\">",
"    <span class=\"h2\">",
"     Psychosocial well being",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer survivors have been shown to experience a number of difficulties that can impact on general quality of life, including depression, anxiety, fatigue, cognitive limitations, sleep problems, pain, and sexual dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/42-48\">",
"     42-48",
"    </a>",
"    ]. However, the data suggest that these needs are not being appropriately addressed.",
"   </p>",
"   <p>",
"    A recent population based study from the 2010 National Health Interview Survey found that poor physical and mental health-related quality of life (HRQOL) were reported by 25 percent and 10 percent of survivors, respectively, compared with 10 percent and 6 percent of adults without cancer (both p&lt;0.0001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of interventions are being evaluated for cancer survivors, including both psychosocial and exercise interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/46,50\">",
"     46,50",
"    </a>",
"    ]. Providers caring for cancer survivors should ask patients about their emotional well being and be prepared to offer additional evaluation, treatment,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    monitoring. Further discussion on specific issues is covered elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychiatric issues (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link\">",
"       \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link\">",
"       \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fatigue (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link\">",
"       \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link\">",
"       \"Cancer-related fatigue: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cognition (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"       \"Evaluation of cognitive impairment and dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sleep disturbances (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=see_link\">",
"       \"Types of insomnia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=see_link\">",
"       \"Treatment of insomnia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"       \"Overview of cancer pain syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"       \"Assessment of cancer pain\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link\">",
"       \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=see_link\">",
"       \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link\">",
"       \"Cancer pain management with opioids: Prevention and management of side effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"       \"Cancer pain management: Interventional therapies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link\">",
"       \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sexual dysfunction (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42904?source=see_link\">",
"       \"The sexual history and approach to the patient with sexual dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418035393\">",
"    <span class=\"h2\">",
"     Fiscal well being",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors may face fiscal issues that interfere with the receipt of healthcare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/51-58\">",
"     51-58",
"    </a>",
"    ]. In one study, 25 percent of cancer survivors reported that they used up all or most of their savings in the process of cancer treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, 10 percent were unable to pay for basic necessities (eg, food, heat, and housing) while 8 percent delayed or avoided care for cancer due to costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/55\">",
"     55",
"    </a>",
"    ]. Among those filing for bankruptcy, the highest out-of-pocket medical expenses were associated with cancer compared to other diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/56\">",
"     56",
"    </a>",
"    ]. Finally, at least one study suggests that cancer survivors &le;65 years were more likely to forego medical care due to costs compared to older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beyond issues related to the financing of cancer care and follow-up, the eligibility of cancer survivors for health, disability, life, or long term care insurance is another critical area of concern. One study found that 12 percent of survivors reported being denied health or life insurance coverage because of their cancer diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/59\">",
"     59",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    Given the issues presented following a diagnosis and treatment for cancer, providers should inquire about financial status of the patients and whether financial difficulties exist. If issues are identified, patients should be referred to local community social workers, case managers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other support services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11934000\">",
"    <span class=\"h1\">",
"     DISEASE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have compared preventive care for comorbid conditions between cancer survivors and those without cancer and have found differences in care by cancer type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/13,14,60-62\">",
"     13,14,60-62",
"    </a>",
"    ]. For example, compared to patients with no history of cancer, patients with a prior history of colorectal cancer (and without evidence of disease for at least five years) were less likely to receive flu shots or undergo colorectal cancer screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the topics that might relate to disease prevention in cancer survivors, the roles of diet, physical activity, smoking cessation, and the management of comorbidities are of paramount importance for the primary care provider and oncology team to be aware of. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2419177549\">",
"    <span class=\"h2\">",
"     Diet and physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to the general population, cancer survivors are as likely to be obese (in one report, the incidence in both populations is up to 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/63\">",
"     63",
"    </a>",
"    ]) and less active (32 versus 24 percent, respectively in another report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/64\">",
"     64",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Decreased activity among cancer survivors may be related to higher rates of fatigue, post chemotherapy weight gain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical limitations, among other factors. However, both diet and physical activity can improve the quality of life and can minimize both disease and treatment-related side effects in cancer survivors. Therefore, clinicians should screen all adult cancer survivors for obesity and offer intensive counseling and behavioral interventions to promote sustained weight loss, which is consistent with the United States Preventative Services Task Force (USPSTF) guidance on obesity for all adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/65\">",
"     65",
"    </a>",
"    ]. The role of physical activity and diet in cancer survivorship is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=see_link\">",
"     \"The roles of diet, physical activity, and body weight in cancer survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2419177565\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer survivors are at increased risk for subsequent cancers, and the risks are significantly higher among those who continue to smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Despite this, one study found that 15 percent of cancer survivors were cigarette smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We concur with the USPSTF and recommend that clinicians ask all adults about tobacco use and provide tobacco cessation interventions for those who use tobacco products, including cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/68\">",
"     68",
"    </a>",
"    ]. Approaches involving both oncology specialists and primary care providers may be useful in guiding patients to quit smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H418030689\">",
"     'Coordination of care'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Detailed overview and specific issues in the promotion of a healthy lifestyle for cancer survivors are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1642769664\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the evidence base for the association between alcohol consumption and cancer incidence, there are few data available regarding the association between alcohol and cancer recurrence. Thus, recommendations for limited alcohol intake in cancer survivors are based primarily on reducing the risk for new primaries. &nbsp;Specifically, for people who drink alcohol, the American Cancer Society recommends limiting consumption to two drinks per day for men and one drink per day for women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=see_link&amp;anchor=H4656216#H4656216\">",
"     \"Overview of the risks and benefits of alcohol consumption\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11934028\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF COMORBID CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers caring for cancer survivors should monitor for and appropriately manage comorbid medical conditions that either were present prior to cancer treatment or those that developed posttreatment.",
"   </p>",
"   <p>",
"    An estimated 54 percent of cancer survivors have a comorbid condition compared to 45 percent of patients without a history of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/72\">",
"     72",
"    </a>",
"    ]. Among cancer survivors, comorbidity was rated as mild, moderate, or severe in 30, 17, and 7 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite the high prevalence of comorbidities among cancer survivors, the quality of care for other conditions beyond cancer has only begun to receive attention in clinical research.",
"   </p>",
"   <p>",
"    Some data suggest that comorbidities increase the risk of all cause mortality in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. For example, the impact of pre-existing diabetes in cancer patients was evaluated in a 2008 meta-analysis that included 23 articles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/73\">",
"     73",
"    </a>",
"    ]. Compared to patients with cancer without pre-existing diabetes, those with diabetes had higher risk of death from any cause (hazard ratio [HR] for all cause mortality 1.41, 95% CI 1.28-1.55).",
"   </p>",
"   <p>",
"    Unfortunately, the limited data suggest that patients with a history of cancer may not be receiving appropriate care for conditions beyond cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/60,75\">",
"     60,75",
"    </a>",
"    ]. In one study, being a cancer survivor was associated with a higher likelihood that a patient was receiving suboptimal care for a chronic medical condition (eg, congestive heart failure or diabetes) (odds ratio [OR] 1.19, 95% CI 1.12-1.27) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/60\">",
"     60",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    It is important that care be coordinated between the oncology team and the primary care provider to ensure that attention to medical conditions beyond cancer is being received. (See",
"    <a class=\"local\" href=\"#H418030697\">",
"     'Shared care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11934042\">",
"    <span class=\"h1\">",
"     GENETIC IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers should inquire about family history of cancer in cancer survivors at the time of diagnosis and update this information over the course of follow-up. Patients with a personal or family history suggesting a potential familial cancer syndrome should be referred for genetic evaluation and testing.",
"   </p>",
"   <p>",
"    Genetic factors may be associated with cancer recurrences and the development of secondary malignancies. In addition, genetic factors may have important implications for the survivors&rsquo; family members. While not currently well defined, the role of genetic factors and their effect on the development of late effects is currently being studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion on genetic counseling and specific cancer syndromes are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418030689\">",
"    <span class=\"h1\">",
"     COORDINATION OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The follow-up of cancer survivors can be shared among the primary care provider, medical oncologist, and other cancer specialists. For example, rehabilitation providers may play an important role in the prevention and management of symptoms and late effects while promoting survivor health and well-being [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies looking at the relationship between physician specialty and the receipt of appropriate care find that survivors receive appropriate care when visits are shared between a primary care provider and an oncology specialist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/10-13,60\">",
"     10-13,60",
"    </a>",
"    ]. However, patients who are followed by generalists tend to receive more preventive care than do patients who are seen primarily by oncologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/10,11,13,14,78,79\">",
"     10,11,13,14,78,79",
"    </a>",
"    ]. Furthermore, many cancer survivors are elderly, and primary care providers may be better equipped to address comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The roles and responsibilities for survivorship care should be well delineated for both patients and their providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/80-82\">",
"     80-82",
"    </a>",
"    ], particularly during transitions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/1\">",
"     1",
"    </a>",
"    ]. For survivors, the transition from oncology to primary care settings should be guided by the survivorship care plan (SCP). The SCP is developed by the oncology team at the completion of treatment and is meant to be shared with the patient and his or her providers, including the primary care physician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/1\">",
"     1",
"    </a>",
"    ]. While limited evidence suggests that the SCPs are beneficial (to primary care providers and shared patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/81,83-88\">",
"     81,83-88",
"    </a>",
"    ], one randomized trial did not show a benefit of SCPs to cancer-related distress or other patient reported outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418030697\">",
"    <span class=\"h2\">",
"     Shared care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care providers may not be comfortable addressing long-term complications from cancer treatment, or may be unaware of recommendations for posttreatment surveillance from organizations such as the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/90\">",
"     90",
"    </a>",
"    ]. A survey that included clinical vignettes, sent to a representative sample of over 2000 primary care providers and oncologists in the United States, found that primary care providers were more likely than oncologists to recommend surveillance studies (blood tests and imaging) of questionable value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A shared care model has been promoted by ASCO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/90\">",
"     90",
"    </a>",
"    ], which encourages communication between the oncology specialist and primary care provider. This model uses a risk-stratified approach and aims to help patients transition from an oncology to a primary care posttreatment setting. Such a model may optimize adherence to guidelines for recommended follow-up care in cancer survivors, although there is low quality evidence to support benefit from such a model of care for patients with chronic diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/91\">",
"     91",
"    </a>",
"    ]. This concept of shared care is also supported by the Institute of Medicine (IOM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If agreed upon by the patient, the treating oncologist, and the primary care provider, shared care would provide treatment summary information and a plan for follow-up care to both the patient and the primary care provider. The level of shared follow-up by the oncology specialist and primary care provider could depend upon patient and provider preferences. Communication between the primary care provider and subspecialist is vital given that uncertainties about physician roles and responsibilities can lead to deficiencies in care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32873/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116772781\">",
"    <span class=\"h1\">",
"     CANCER-SPECIFIC INFORMATION FOR SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate covers survivorship issues in some of the more common cancers. Links to these topics are listed below.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36394?source=see_link\">",
"     Overview of the approach to the adult survivor of classical Hodgkin lymphoma",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4185?source=see_link\">",
"     Overview of care for adult survivors of non-Hodgkin lymphoma",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=see_link\">",
"     The approach to hematopoietic cell transplantation survivorship",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     Approach to the long-term survivor of breast cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28202?source=see_link\">",
"     Approach to the long-term survivor of colorectal cancer",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/41/16025?source=see_link\">",
"     Approach to the care of long-term testicular cancer survivors",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11934056\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The population of cancer survivors is growing and getting older. Surveillance for recurrences and other cancers, disease prevention, management of comorbid medical conditions, and monitoring for physical and psychological effects of cancer treatment is needed. (See",
"      <a class=\"local\" href=\"#H11933956\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease recurrences typically occur within the first five years after treatment. Secondary cancers and late effects may occur years later. (See",
"      <a class=\"local\" href=\"#H11933979\">",
"       'Risk of recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late effects of cancer treatment may include cardiomyopathy, peripheral neuropathy,",
"      <span class=\"nowrap\">",
"       infertility/menopause,",
"      </span>",
"      among others. Providers need to remain vigilant about signs and symptoms and offer evaluation promptly. (See",
"      <a class=\"local\" href=\"#H418032179\">",
"       'Monitoring for long term and late effects of cancer and its treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychological effects of cancer are common, and may include depression, anxiety, fatigue, cognitive limitations, sleep problems, pain, and sexual dysfunction. Evaluation of symptoms and management is needed. Financial implications on care must be addressed. (See",
"      <a class=\"local\" href=\"#H418032811\">",
"       'Psychosocial well being'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lifestyle modification, including smoking cessation, healthy diet, exercise, and no more than moderate alcohol consumption, is important for cancer survivors. They have been shown to improve patient quality of life, risk of recurrences, and possibly mortality. (See",
"      <a class=\"local\" href=\"#H11934000\">",
"       'Disease prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coordination with primary care particularly for prevention, management of comorbid medical conditions, and psychosocial care may be of benefit. Survivorship care plans are a tool to communicate and guide survivorship care. (See",
"      <a class=\"local\" href=\"#H418030689\">",
"       'Coordination of care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hewitt, M, Greenfield, S, Stovall, E, et al. From cancer patient to cancer survivor: Lost in transition. (National Academies Press, Washington DC), 2006 file://www.iom.edu/Reports/2005/From-Cancer-Patient-to-Cancer-Survivor-Lost-in-Transition.aspx (Accessed on January 31, 2011).",
"    </li>",
"    <li>",
"     American Cancer Society. Cancer Treatment and Survivorship Facts &amp; Figures 2012-2013. American Cancer Society; Atlanta, GA 2012.",
"    </li>",
"    <li>",
"     World estimated cancer prevalence, adult population: both sexes. file://globocan.iarc.fr/summary_table_pop_prev.asp?selection=225900&amp;title=World&amp;sex=0&amp;window=1&amp;sort=0&amp;submit=%A0Execute%A0 (Accessed on February 13, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/4\">",
"      Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/5\">",
"      Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009; 27:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/6\">",
"      Elston Lafata J, Simpkins J, Schultz L, et al. Routine surveillance care after cancer treatment with curative intent. Med Care 2005; 43:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/7\">",
"      Salloum RG, Hornbrook MC, Fishman PA, et al. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer 2012; 118:5644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/8\">",
"      Keating NL, Landrum MB, Guadagnoli E, et al. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol 2007; 25:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/9\">",
"      Cooper GS, Kou TD, Reynolds HL Jr. Receipt of guideline-recommended follow-up in older colorectal cancer survivors : a population-based analysis. Cancer 2008; 113:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/10\">",
"      Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol 2008; 26:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/11\">",
"      Snyder CF, Earle CC, Herbert RJ, et al. Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med 2008; 23:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/12\">",
"      Snyder CF, Frick KD, Kantsiper ME, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 2009; 27:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/13\">",
"      Snyder CF, Frick KD, Peairs KS, et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med 2009; 24:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/14\">",
"      Snyder CF, Frick KD, Herbert RJ, et al. Preventive care in prostate cancer patients: following diagnosis and for five-year survivors. J Cancer Surviv 2011; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/15\">",
"      Keating NL, Landrum MB, Guadagnoli E, et al. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol 2006; 24:85.",
"     </a>",
"    </li>",
"    <li>",
"     Bleyer A, O&rsquo;Leary M, Barr R, et al.. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. National Cancer Institute; Bethesda, MD 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/17\">",
"      Desch CE, Benson AB 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23:8512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/18\">",
"      Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: american society of clinical oncology clinical practice guideline update. J Clin Oncol 2013; 31:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/19\">",
"      Potosky AL, Han PK, Rowland J, et al. Differences between primary care physicians' and oncologists' knowledge, attitudes and practices regarding the care of cancer survivors. J Gen Intern Med 2011; 26:1403.",
"     </a>",
"    </li>",
"    <li>",
"     Travis LB, Bhatia S, Allan JM, et al.. Second Primary Cancers. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 9th, DePinho RA, Lawrence TS, Rosenberg SA, Weinberg RA.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.2393-2410.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/21\">",
"      Wood ME, Vogel V, Ng A, et al. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 2012; 30:3734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/22\">",
"      Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/23\">",
"      Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/24\">",
"      Chuang SC, Scelo G, Tonita JM, et al. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer 2008; 123:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/25\">",
"      Doubeni CA, Field TS, Ulcickas Yood M, et al. Patterns and predictors of mammography utilization among breast cancer survivors. Cancer 2006; 106:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/26\">",
"      Grunfeld E, Hodgson DC, Del Giudice ME, Moineddin R. Population-based longitudinal study of follow-up care for breast cancer survivors. J Oncol Pract 2010; 6:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/27\">",
"      Oeffinger KC, Ford JS, Moskowitz CS, et al. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA 2009; 301:404.",
"     </a>",
"    </li>",
"    <li>",
"     Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers. Version 3.0, Children's Oncology Group; Arcadia, CA 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/29\">",
"      Bhatia S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev 2011; 20:2048.",
"     </a>",
"    </li>",
"    <li>",
"     Yahalom J, Portlock CS. Toxicity. In: DeVita, Hellman, and Rosenberg's Cancer: Principles &amp; Practice of Oncology, 9th, DePinho RA, Lawrence TS, Rosenberg SA, Weinberg RA.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.2360-2368.",
"    </li>",
"    <li>",
"     Norian JM, Feinberg EC, DeCherney AH, Armstrong AY. Gonadal Dysfunction. In: De Vita, Hellman, and Rosenberg's Cancer: Principles &amp; Practice of Oncology, 9th, DePinho RA, Lawrence TS, Rosenberg SA, Weinberg RA.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.2372-2387.",
"    </li>",
"    <li>",
"     Stubblefield MD. Rehabilitation of the Cancer Patient. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 9th, DePinho RA, Lawrence TS, Rosenberg SA, Weinberg RA.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.2503-2509.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/33\">",
"      Ruddy KJ, Partridge AH. Fertility (male and female) and menopause. J Clin Oncol 2012; 30:3705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/34\">",
"      Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol 2012; 30:3687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/35\">",
"      Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. J Clin Oncol 2012; 30:3657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/36\">",
"      Nathan PC, Greenberg ML, Ness KK, et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2008; 26:4401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/37\">",
"      Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/38\">",
"      Ganz PA. Pediatric cancer survivorship: the Childhood Cancer Survivor Study--editor's foreword. J Clin Oncol 2009; 27:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/39\">",
"      Ganz PA, Earle CC, Goodwin PJ. Journal of Clinical Oncology update on progress in cancer survivorship care and research. J Clin Oncol 2012; 30:3655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/40\">",
"      Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/41\">",
"      Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/42\">",
"      Harrington CB, Hansen JA, Moskowitz M, et al. It's not over when it's over: long-term symptoms in cancer survivors--a systematic review. Int J Psychiatry Med 2010; 40:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/43\">",
"      Brown LF, Kroenke K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 2009; 50:440.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine of the National Academies Board on Health Care Services. Cancer care for the whole patient: meeting psychosocial health needs. The National Academies Press; Washington, D.C., 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/45\">",
"      Foster C, Wright D, Hill H, et al. Psychosocial implications of living 5 years or more following a cancer diagnosis: a systematic review of the research evidence. Eur J Cancer Care (Engl) 2009; 18:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/46\">",
"      Stanton AL. What happens now? Psychosocial care for cancer survivors after medical treatment completion. J Clin Oncol 2012; 30:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/47\">",
"      Carlson LE, Waller A, Mitchell AJ. Screening for distress and unmet needs in patients with cancer: review and recommendations. J Clin Oncol 2012; 30:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/48\">",
"      Jacobsen PB, Holland JC, Steensma DP. Caring for the whole patient: the science of psychosocial care. J Clin Oncol 2012; 30:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/49\">",
"      Weaver KE, Forsythe LP, Reeve BB, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2012; 21:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/50\">",
"      Craft LL, Vaniterson EH, Helenowski IB, et al. Exercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012; 21:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/51\">",
"      Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002; 40:IV.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/52\">",
"      Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22:3524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/53\">",
"      Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007; 25:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/54\">",
"      Langa KM, Fendrick AM, Chernew ME, et al. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health 2004; 7:186.",
"     </a>",
"    </li>",
"    <li>",
"     The USA Today/Kaiser Family Foundation/Harvard School of Public Health. National Survey of Households Affected by Cancer. 2006",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/56\">",
"      Himmelstein DU, Warren E, Thorne D, Woolhandler S. Illness and injury as contributors to bankruptcy. Health Aff (Millwood) 2005; Suppl Web Exclusives:W5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/57\">",
"      Weaver KE, Rowland JH, Bellizzi KM, Aziz NM. Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States. Cancer 2010; 116:3493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/58\">",
"      Nekhlyudov L, Madden J, Graves AJ, et al. Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. J Cancer Surviv 2011; 5:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/59\">",
"      Underwood JM, Townsend JS, Stewart SL, et al. Surveillance of demographic characteristics and health behaviors among adult cancer survivors--Behavioral Risk Factor Surveillance System, United States, 2009. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/60\">",
"      Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer 2004; 101:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/61\">",
"      Yu X, McBean AM, Virnig BA. Physician visits, patient comorbidities, and mammography use among elderly colorectal cancer survivors. J Cancer Surviv 2007; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/62\">",
"      Duffy CM, Clark MA, Allsworth JE. Health maintenance and screening in breast cancer survivors in the United States. Cancer Detect Prev 2006; 30:52.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/mm59e0803a1.htm (Accessed on February 13, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/64\">",
"      Centers for Disease Control and Prevention (CDC). Prevalence of physical activity, including lifestyle activities among adults--United States, 2000-2001. MMWR Morb Mortal Wkly Rep 2003; 52:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/65\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/66\">",
"      Klosky JL, Tyc VL, Garces-Webb DM, et al. Emerging issues in smoking among adolescent and adult cancer survivors: a comprehensive review. Cancer 2007; 110:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/67\">",
"      Mariotto AB, Rowland JH, Ries LA, et al. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007; 16:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/68\">",
"      U.S. Preventive Services Task Force. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009; 150:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/69\">",
"      Demark-Wahnefried W, Pinto BM, Gritz ER. Promoting health and physical function among cancer survivors: potential for prevention and questions that remain. J Clin Oncol 2006; 24:5125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/70\">",
"      Doyle C, Kushi LH, Byers T, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 2006; 56:323.",
"     </a>",
"    </li>",
"    <li>",
"     Alcohol use and cancer. file://www.cancer.org/cancer/cancercauses/dietandphysicalactivity/alcohol-use-and-cancer (Accessed on March 06, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/72\">",
"      Yabroff KR, Lawrence WF, Clauser S, et al. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 2004; 96:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/73\">",
"      Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300:2754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/74\">",
"      Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/75\">",
"      Snyder CF, Frick KD, Herbert RJ, et al. Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. J Clin Oncol 2013; 31:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/76\">",
"      Armenian SH, Bhatia S. Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role? J Gen Intern Med 2009; 24 Suppl 2:S395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/77\">",
"      Alfano CM, Ganz PA, Rowland JH, Hahn EE. Cancer survivorship and cancer rehabilitation: revitalizing the link. J Clin Oncol 2012; 30:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/78\">",
"      Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 2003; 21:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/79\">",
"      Khan NF, Carpenter L, Watson E, Rose PW. Cancer screening and preventative care among long-term cancer survivors in the United Kingdom. Br J Cancer 2010; 102:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/80\">",
"      Cheung WY, Neville BA, Cameron DB, et al. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 2009; 27:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/81\">",
"      Kantsiper M, McDonald EL, Geller G, et al. Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 2009; 24 Suppl 2:S459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/82\">",
"      Bober SL, Recklitis CJ, Campbell EG, et al. Caring for cancer survivors: a survey of primary care physicians. Cancer 2009; 115:4409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/83\">",
"      Baravelli C, Krishnasamy M, Pezaro C, et al. The views of bowel cancer survivors and health care professionals regarding survivorship care plans and post treatment follow up. J Cancer Surviv 2009; 3:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/84\">",
"      Del Giudice ME, Grunfeld E, Harvey BJ, et al. Primary care physicians' views of routine follow-up care of cancer survivors. J Clin Oncol 2009; 27:3338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/85\">",
"      Hewitt ME, Bamundo A, Day R, Harvey C. Perspectives on post-treatment cancer care: qualitative research with survivors, nurses, and physicians. J Clin Oncol 2007; 25:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/86\">",
"      Watson EK, Sugden EM, Rose PW. Views of primary care physicians and oncologists on cancer follow-up initiatives in primary care: an online survey. J Cancer Surviv 2010; 4:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/87\">",
"      Shalom MM, Hahn EE, Casillas J, Ganz PA. Do survivorship care plans make a difference? A primary care provider perspective. J Oncol Pract 2011; 7:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/88\">",
"      Mayer DK, Gerstel A, Leak AN, Smith SK. Patient and provider preferences for survivorship care plans. J Oncol Pract 2012; 8:e80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/89\">",
"      Grunfeld E, Julian JA, Pond G, et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol 2011; 29:4755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/90\">",
"      McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 2013; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32873/abstract/91\">",
"      Smith SM, Allwright S, O'Dowd T. Effectiveness of shared care across the interface between primary and specialty care in chronic disease management. Cochrane Database Syst Rev 2007; :CD004910.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16613 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32873=[""].join("\n");
var outline_f32_6_32873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11934056\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11933956\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11933963\">",
"      EPIDEMIOLOGY OF CANCER SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H418030573\">",
"      GUIDELINES FOR POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11933970\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11933979\">",
"      Risk of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11933986\">",
"      Cancer surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H418032179\">",
"      Monitoring for long term and late effects of cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H418032811\">",
"      Psychosocial well being",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H418035393\">",
"      Fiscal well being",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11934000\">",
"      DISEASE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2419177549\">",
"      Diet and physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2419177565\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1642769664\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11934028\">",
"      MANAGEMENT OF COMORBID CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11934042\">",
"      GENETIC IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H418030689\">",
"      COORDINATION OF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H418030697\">",
"      Shared care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116772781\">",
"      CANCER-SPECIFIC INFORMATION FOR SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11934056\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16613|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/12/23757\" title=\"table 1\">",
"      Late effects RT CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/41/16025?source=related_link\">",
"      Approach to the care of long-term testicular cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28202?source=related_link\">",
"      Approach to the long-term survivor of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4185?source=related_link\">",
"      Overview of care for adult survivors of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36394?source=related_link\">",
"      Overview of the approach to the adult survivor of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=related_link\">",
"      The roles of diet, physical activity, and body weight in cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42904?source=related_link\">",
"      The sexual history and approach to the patient with sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_6_32874="Overview of Hodgkin lymphoma in children and adolescents";
var content_f32_6_32874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of Hodgkin lymphoma in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32874/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32874/contributors\">",
"     Stephen M Gottschalk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32874/contributors\">",
"     Kenneth L McClain, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32874/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32874/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/6/32874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/6/32874/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/6/32874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (HL, formerly called Hodgkin's disease) is a malignant lymphoma that accounts for approximately 7 percent of childhood cancers and 1 percent of childhood cancer deaths in the United States (",
"    <a class=\"graphic graphic_table graphicRef69839 \" href=\"mobipreview.htm?31/51/32572\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The incidence of HL in childhood varies by age such that HL is exceedingly rare in infants, but is the most common childhood cancer in the 15- to 19-year-old age group.",
"   </p>",
"   <p>",
"    Few risk factors, other than those related to viral exposure and immune function, have been convincingly identified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3703?source=see_link\">",
"     \"The role of Epstein-Barr virus in Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide an overview of HL in children and adolescents. The pathobiology of HL and its diagnosis and management in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1407815041\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variation in the incidence, age, and sex distribution of HL occurs in different populations according to geographic location, socioeconomic status, and immunologic status. The incidence of all childhood cancers has been gradually rising since 1975 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/3\">",
"     3",
"    </a>",
"    ]. In the United States and other economically advantaged countries, two incidence peaks exist: one in young adults and one in older age; most patients are young adults (",
"    <a class=\"graphic graphic_figure graphicRef62585 \" href=\"mobipreview.htm?29/42/30383\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/4\">",
"     4",
"    </a>",
"    ]. The bimodal age distribution of HL is different in economically disadvantaged areas. An initial peak occurs in childhood for boys, relatively low rates are found in young adults, and a late peak occurs in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\", section on 'Incidence and age distribution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States between 1992 and 2004, the annual incidence of HL among children younger than 20 years of age was 11.7 per million; HL was the most common childhood cancer in the 15- to 19-year age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/2\">",
"     2",
"    </a>",
"    ]. The overall incidence of HL in children is greater in females than in males (male to female ratio 0.8); however, the sex distribution is age-dependent, with a male-to-female ratio of 0.8, 1.3, and 5.3 among children aged 15 to 19 years, younger than 15 years, and younger than five years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence of HL is similar among black and white children younger than 10 years of age, but is increased among white children older than 10 years (white to black ratio of 1.4:1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial HL has been estimated to represent 4.5 percent of all cases of HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This familial association may include shared environmental factors, exposure to viruses, and genetic influences, including inherited immunodeficiency states. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\", section on 'Risk in family members'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3703?source=see_link\">",
"     \"The role of Epstein-Barr virus in Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary humoral immune deficiencies: An overview\", section on 'Hyperimmunoglobulin M syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant cells of HL are clonal",
"    <span class=\"nowrap\">",
"     Hodgkin/Reed-Sternberg",
"    </span>",
"    (HRS) cells (",
"    <a class=\"graphic graphic_picture graphicRef63379 \" href=\"mobipreview.htm?41/18/42276\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77200 \" href=\"mobipreview.htm?27/58/28578\">",
"     picture 2",
"    </a>",
"    ), which usually constitute less than 1 percent of the cells in involved lymph nodes. The rest of the lymph node contains a variable cellular infiltrate consisting of lymphocytes, eosinophils, macrophages, plasma cells, and fibroblasts. These infiltrating cells secrete an array of cytokines and chemokines, which are important for HRS cell survival and maintenance of the characteristic cellular infiltrate. The biology of HRS cells and their role in HL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epstein-Barr virus (EBV) infection is associated with HL, can be detected in HRS cells, and is thought to play a role in the pathogenesis of HL. Twenty-five to 50 percent of cases of classical HL in developed countries are EBV positive; the incidence of EBV varies among histological subtypes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3703?source=see_link&amp;anchor=H8#H8\">",
"     \"The role of Epstein-Barr virus in Hodgkin lymphoma\", section on 'Incidence of EBV positivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1407816399\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL is a lymphoid neoplasm defined histopathologically by the presence of clonal malignant",
"    <span class=\"nowrap\">",
"     Hodgkin/Reed-Sternberg",
"    </span>",
"    (HRS) cells (",
"    <a class=\"graphic graphic_picture graphicRef63379 \" href=\"mobipreview.htm?41/18/42276\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77200 \" href=\"mobipreview.htm?27/58/28578\">",
"     picture 2",
"    </a>",
"    ) with a variable cellular infiltrate consisting of lymphocytes, eosinophils, macrophages, plasma cells, and fibroblasts. HRS cells, which usually constitute less than 1 percent of the cells in involved lymph nodes, secrete an array of cytokines and chemokines, which are important for HRS cell survival and maintenance of the characteristic cellular infiltrate.",
"   </p>",
"   <p>",
"    The WHO classification of lymphomas divides HL into classical HL and nodular lymphocyte predominant HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with nodular lymphocyte predominant HL appear to have a better outcome, and their treatment may vary from those with classical HL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification of the hematopoietic neoplasms\", section on 'Hodgkin lymphoma (HL)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1407816406\">",
"    <span class=\"h2\">",
"     Classical HL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical HL occurs more commonly (90 to 95 percent of cases) than nodular lymphocyte predominant HL and is subdivided into four subtypes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nodular sclerosis (NS)",
"     </li>",
"     <li>",
"      Mixed cellularity (MC)",
"     </li>",
"     <li>",
"      Lymphocyte depleted (LD)",
"     </li>",
"     <li>",
"      Lymphocyte rich (LR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As in adults, NS is the most common form of pediatric HL, representing 70 to 80 percent of cases in adolescents and 40 to 50 percent of cases in children younger than 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence of MC decreases with age, from 30 to 35 percent in younger children to 10 to 15 percent in adolescents. LD and LR are rare events, accounting for fewer than 5 percent of all HL cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1407816413\">",
"    <span class=\"h2\">",
"     Nodular lymphocyte predominant HL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular lymphocyte predominant HL (NLPHL) accounts for 5 to 10 percent of HL cases. The malignant cells seen in NLPHL have distinct characteristics that separate them from the more classic Reed-Sternberg cells of HL (",
"    <a class=\"graphic graphic_table graphicRef57079 \" href=\"mobipreview.htm?17/23/17788\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1407815786\">",
"    <span class=\"h1\">",
"     PRESENTING SYMPTOMS AND SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presenting symptoms and signs of HL in children include lymphadenopathy, systemic complaints, and mediastinal mass. HL almost always presents at a site above the diaphragm, with only approximately 3 percent of cases presenting in a subdiaphragmatic location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with HL present with painless lymphadenopathy, usually cervical, supraclavicular, axillary, or, less often, inguinal. The affected lymph nodes typically feel rubbery and more firm than inflammatory adenopathy; they may be sensitive to palpation if they have grown rapidly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Lymph nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hepatosplenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenic enlargement may be present in patients with advanced stage HL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12840?source=see_link\">",
"     \"Approach to the child with an enlarged spleen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mediastinal mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 75 percent of children with HL have a mediastinal mass on chest radiograph at the time of presentation. Mediastinal masses are almost always present in association with low cervical or supraclavicular adenopathy. They are more common occurrences among children older than 12 years of age, in whom approximately 30 percent have masses that are greater than one-third the diameter of the intrathoracic cavity. Such \"bulky\" mediastinal disease may cause dysphagia, dyspnea, cough, stridor, or the superior vena cava syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with intrathoracic HL also rarely present with hypertrophic osteoarthropathy, a syndrome characterized by abnormal proliferation of the skin and osseous tissue at the distal parts of the extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Clinical features of hypertrophic osteoarthropathy include digital clubbing and periostosis of tubular bones, which usually is accompanied by pain on palpation of the involved area. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"     \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HL may present with nonspecific systemic symptoms including fatigue, anorexia, and weight loss. Fewer than 20 percent of children with HL have the classic fever and night sweats that are seen in adults. However, these symptoms along with weight loss (ie, \"B\" symptoms) have important implications for staging and prognosis (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link&amp;anchor=H13#H13\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Criteria for B symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in adults, pruritus and alcohol-induced pain, which typically resolve with treatment, have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/568?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\", section on 'Other nonspecific symptoms and paraneoplastic syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients present with autoimmune disorders such as autoimmune hemolytic anemia, thrombocytopenia, or neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms and signs of HL in children and adolescents may be caused by a variety of diseases and the differential diagnosis includes other malignant, infectious, and inflammatory diseases. They include non-Hodgkin lymphoma, metastatic adenopathy from other primary tumors (eg, nasopharyngeal carcinoma, soft tissue sarcoma), toxoplasmosis, typical and atypical mycobacterium infections, EBV infection, systemic lupus erythematosus, and disorders causing reactive hyperplasia of lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/19\">",
"     19",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Chest radiographs should be obtained in all patients in whom a diagnosis of HL is being considered. The diagnostic considerations in patients with mediastinal masses depend upon the anatomic compartment in which the mass is located (",
"    <a class=\"graphic graphic_figure graphicRef56637 \" href=\"mobipreview.htm?10/31/10743\">",
"     figure 2",
"    </a>",
"    ). In children, anterior mediastinal mass must be distinguished from normal thymus, which attains maximal size when the child reaches approximately 10 years of age. Computed tomography (CT)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other imaging studies may be necessary to make this distinction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete evaluation of patients with suspected HL is mandatory before beginning treatment. The goal is to evaluate the extent of disease, which, in turn, determines the clinical and pathologic stage, treatment, and to a great extent, prognosis.",
"   </p>",
"   <p>",
"    The evaluation should be undertaken at a center where a team of pediatric oncologists, pathologists, surgeons, radiotherapists, nurses, and social workers are experienced in the diagnosis and care of children with cancer. The superior results of children with malignancies treated in pediatric oncology centers as opposed to community hospitals is well documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine evaluation of a patient with suspected HL should include a complete history, with emphasis on constitutional symptoms such as fever, night sweats, weight loss, previous infections, family exposures to toxins, and parental occupational hazards, as well as evidence of underlying immune deficiencies and familial cancer, including HL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination includes assessment of general health, measurement of height and weight, and documentation of the size and location of lymphadenopathy (",
"    <a class=\"graphic graphic_figure graphicRef55422 \" href=\"mobipreview.htm?41/2/42021\">",
"     figure 3",
"    </a>",
"    ), liver and spleen size, skin infiltrations, pulmonary findings, and neurologic signs. The tonsils, base of the tongue, and nasopharynx (ie, Waldeyer's ring) must be included in this evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HL is established by histologic examination, usually excisional biopsy of an enlarged lymph node that demonstrates malignant \"classic\" HRS cells or their variants, which may represent only a minority (usually less than 1 percent) of the cellular infiltrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/9\">",
"     9",
"    </a>",
"    ]. Subclassification of HL depends upon whether the overall pattern is nodular, diffuse, or both, and whether \"classic\" or variant Reed-Sternberg cells are present, as well as the composition of the cellular infiltrate (eg, non-neoplastic small lymphocytes, eosinophils, plasma cells, fibroblasts, histiocytes, neutrophils, and collagen fibers). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a large mediastinal mass are at risk for acute respiratory compromise. The evaluation and biopsy of these patients must be undertaken with special care. These patients may have assumed an awkward seated position that allows them to keep an open airway. Such patients should NEVER be laid down. A biopsy of a superficial node under local anesthesia may be required. Occasionally, such patients need urgent radiotherapy to part of the mediastinal mass.",
"   </p>",
"   <p>",
"    Bone marrow aspirates are recommended only for patients with advanced stage disease (Stage III, IV), B-symptoms, or any abnormality on the complete blood count that is suspicious for bone marrow involvement (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Staging'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in diagnostic imaging and the use of systemic chemotherapy in all pediatric HL treatment protocols have made routine staging laparotomy unnecessary. We would consider a laparotomy in patients with one of the following findings to assure accurate staging before therapy (Pediatric Oncology Group [POG] protocols",
"    <span class=\"nowrap\">",
"     9425/9426):",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intra-abdominal lymph nodes between one and three centimeters (Lymph nodes &gt;3 cm are assumed to be positive unless pathology proves them negative.)",
"     </li>",
"     <li>",
"      Focal abnormalities of the liver may require biopsy of a specific area that could be done by CT-guided needle biopsy",
"     </li>",
"     <li>",
"      Areas of uptake in the abdomen on the gallium scan not explained by other diagnostic studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory tests, including complete blood count with white blood cell differential and platelet count, erythrocyte sedimentation rate, renal and liver function tests, lactate dehydrogenase (LDH), and urinalysis, should be obtained. Many of these tests are used to determine the presence or absence of organ involvement, as well as the propensity of the patient to relapse following conventional treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link&amp;anchor=H9398216#H9398216\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not routinely studied, patients may have evidence of an impaired cellular immune system, including decreased T-cell and NK-cell function. We suggest that patients who have a past medical history of recurrent infections, autoimmune and inflammatory disorders, or a family history of immune deficiency undergo a detailed immunologic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of imaging is to define the extent of disease. The following studies should be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest radiograph (anteroposterior and lateral)",
"     </li>",
"     <li>",
"      Computed tomography (CT) of the primary site (with and without intravenous contrast)",
"     </li>",
"     <li>",
"      CT of thorax, abdomen, and pelvis (with and without intravenous and oral contrast)",
"     </li>",
"     <li>",
"      Positron emission tomography (PET) scan (either as an integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      or as a separate PET study)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The chest radiograph provides information about intrathoracic structures, extent of mediastinal involvement, and patency of the airway (which must be ensured in patients with mediastinal masses before they are sedated for diagnostic tests or procedures). The CT provides information about extranodal sites of disease; the most common sites of extranodal disease are the pulmonary parenchyma, chest wall, pleura, and pericardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For initial staging, CTs of the neck, chest, abdomen, and pelvis are needed, as well as a PET scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. PET scan is especially sensitive for sites of lymphoma in the neck and mediastinum, as well as unsuspected areas in the spleen and bone. PET scans have taken the place of lymphangiograms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29206?source=see_link&amp;anchor=H7#H7\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy and prognosis are based upon the stage of the disease, as currently defined by the Cotswolds classification used both in children and adults (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with HL should be treated in a comprehensive pediatric oncology center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/28\">",
"     28",
"    </a>",
"    ]. However, depending upon referral patterns and center-specific policies, adolescents with HL may be treated with either adult or pediatric treatment protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/29\">",
"     29",
"    </a>",
"    ]. Optimal therapy involves a multidisciplinary approach from the time of diagnosis. Assignment of stage and treatment are best determined after the medical and radiation oncologists have examined the patient and reviewed the diagnostic images and staging study results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H735857\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pediatric oncology centers use a risk-adapted treatment approach. While the specific definitions of low-, intermediate-, and high-risk disease vary by center and study, most stratify children and adolescents based upon stage and the presence or absence of bulky disease as defined by the Ann Arbor staging system with Cotswolds modifications (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 3",
"    </a>",
"    ). For our purposes, we suggest the following risk stratification:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk disease &mdash; Nonbulky stage IA or IIA disease (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Low risk disease'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Intermediate risk disease &mdash; Stage IB or IIB disease; bulky stage IA or bulky stage IIA disease; stage IIAE, stage IIIA, or stage IVA disease, regardless of bulk (see",
"      <a class=\"local\" href=\"#H9978541\">",
"       'Intermediate risk disease'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      High risk disease &mdash; Stage IIIB or stage IVB disease (see",
"      <a class=\"local\" href=\"#H24\">",
"       'High risk disease'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment options for patients in each of these risk groups are presented in more detail in the following sections. High-dose radiation therapy and combination chemotherapy with MOPP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) are no longer used for the treatment of children or adults with newly diagnosed HL due to high rates of long-term side effects and the development of less toxic therapies that maintain efficacy. The ABVD (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) regimen employed in adults has been used successfully in pediatric HL; however, concerns about potential ABVD-related toxicities have led to the development of risk-adapted regimens with reduced chemotherapy and radiation therapy doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Patients with nodular lymphocyte predominant HL appear to have a better outcome and require specific consideration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34520?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma\", section on 'Prognosis'",
"    </a>",
"    .) Current treatment recommendations are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef85775 \" href=\"mobipreview.htm?17/13/17629\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Low risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with nonbulky Ann Arbor stage IA or IIA HL are considered to have early stage, low risk (no bulk; no B symptoms) disease; in some studies, selected stage IIIA patients are also included (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 3",
"    </a>",
"    ). For children with stage I and IIA (early) HL, the event-free survival (EFS) rates are approximately 92 percent with an overall survival (OS) rate of approximately 98 percent with current treatment protocols.",
"   </p>",
"   <p>",
"    Most protocols use combination chemotherapy plus low dose involved field radiation therapy (LD-IFRT). Commonly used regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four cycles of VAMP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) plus LD-IFRT administered after the second cycle of chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Four cycles of COPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"        prednisone",
"       </a>",
"       )/ABV",
"      </span>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ) plus LD-IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ABVE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ), administered for two to four courses depending on response, followed by LD-IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      OEPA (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ; for males) or OPPA (vincristine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , prednisone, doxorubicin; for females) followed by LD-IFRT, depending upon the initial response to chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice among these regimens is largely made based upon physician experience, cancer center preference, and expected toxicities.",
"   </p>",
"   <p>",
"    Given the potential long-term toxicities associated with radiation therapy, researchers have tried to identify a group of patients for whom radiation may be eliminated without compromising survival. Ongoing trials are evaluating whether interim imaging with computed tomography (CT)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positron emission tomography (PET) can identify such a population. As an example, early results from the Children&rsquo;s Oncology Group (COG) AHOD0031 trial suggest that consolidation radiation therapy may not be necessary in patients who show a complete response on CT scan after two cycles of ABVE-PC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) and are PET negative after two additional cycles of ABVE-PC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9978541\">",
"    <span class=\"h2\">",
"     Intermediate risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intermediate risk group comprises patients with stage IB or IIB disease; bulky stage IA or bulky stage IIA disease; stage IIAE, stage IIIA, or stage IVA disease, regardless of bulk. With current treatment strategies, the event-free survival (EFS) rates are approximately 85 percent with an overall survival (OS) rate of approximately 93 percent.",
"   </p>",
"   <p>",
"    Most protocols use more intensive combination chemotherapy plus low dose involved field radiation therapy (LD-IFRT). Commonly used regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Six cycles of COPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"        prednisone",
"       </a>",
"       )/ABV",
"      </span>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ) plus LD-IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ABVE-PC (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ), administered for three to five courses depending upon response, followed by LD-IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two cycles of OEPA (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ; for males) or OPPA (vincristine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , prednisone, doxorubicin; for females), followed by two cycles of COPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , vincristine, procarbazine, prednisone; for females) or COPDAC (cyclophosphamide, vincristine, prednisone,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ; for males), plus LD-IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/36,37,39\">",
"       36,37,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice among these regimens is largely made based upon physician experience, cancer center preference, and expected toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     High risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Ann Arbor stage IIIB disease or IVB disease are considered to have high risk or advanced stage HL. With current treatment strategies, the event-free survival (EFS) rates are approximately 83 percent with an overall survival (OS) rate of approximately 94 percent.",
"   </p>",
"   <p>",
"    Most protocols incorporate high intensity combination chemotherapy plus low-dose (LD-IFRT) or standard dose involved field radiation therapy (IFRT). Commonly used regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABVE-PC (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ), administered for three to five courses depending upon response, followed by LD-IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two cycles of OEPA (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ; for males) or OPPA (vincristine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , prednisone, doxorubicin; for females), followed by two cycles of COPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , vincristine, procarbazine, prednisone; for females) or COPDAC (cyclophosphamide, vincristine, prednisone,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ; for males), plus LD-IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/36,37,39\">",
"       36,37,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two cycles of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"        cytarabine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"        etoposide",
"       </a>",
"       ,",
"      </span>",
"      COPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"        prednisone",
"       </a>",
"       )/ABV",
"      </span>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ), and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and LD-IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Four cycles of BEACOPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) with subsequent therapy dependent upon response; rapid responders: four cycles of",
"      <span class=\"nowrap\">",
"       COPP/ABV",
"      </span>",
"      without IFRT (females) or two cycles of ABVD (doxorubicin, bleomycin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) with IFRT (males); slow responders: four additional cycles of BEACOPP plus IFRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice among these regimens is largely made based upon physician experience, cancer center preference, and expected toxicities. Other regimens that limit doses of alkylating agents, anthracyclines,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation in children with advanced and unfavorable disease have led to inferior outcomes compared with standard regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Relapsed or refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory (resistant) HL is defined as those patients who fail to obtain a complete response with initial therapy or those who relapse within three months from the end of therapy. In contrast, relapsed HL describes the reappearance of HL greater than three months after the attainment of a complete response. The treatment of refractory and relapsed HL depends upon prior therapy, but typically involves the use of non-cross-resistant combination chemotherapy.",
"   </p>",
"   <p>",
"    A variety of chemotherapy protocols using agents not part of initial treatment regimens include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    at moderate or high doses,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Often second line chemotherapy is followed by high dose chemotherapy and subsequent autologous hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Autologous source of stem cells is preferable to allogeneic because of the associated increase chance of transplant related mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of children with",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    HL addresses three different situations:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary progressive disease (refractory HL)",
"     </li>",
"     <li>",
"      Relapse in only sites of initial involvement for patients treated with chemotherapy alone",
"     </li>",
"     <li>",
"      Other relapses",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with primary refractory disease have poor outcomes with second line therapy even if peripheral blood HCT and radiation are employed. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A study of 82 patients with refractory HL reported that aggressive second-line therapy (high-dose chemoradiotherapy) followed by autologous HCT resulted in a five-year overall survival rate of 49 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, patients with primary refractory HL treated with chemotherapy plus radiation therapy had 10-year event-free and overall survival rates of 41 percent and 51 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with primary refractory HL that is chemosensitive to standard dose second-line chemotherapy have superior survival rates (66 percent overall survival) than those who remain refractory (17 percent overall survival) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of second line therapy for patients who relapse depends upon the timing of relapse, the initial stage of disease, and the initial treatment given. Patients who relapse within the first year from diagnosis are known as &ldquo;early relapsers&rdquo; and have 10-year event-free and overall survival rates of 55 and 78 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/52\">",
"     52",
"    </a>",
"    ]. In comparison, those relapsing after the first year have 10-year event-free and overall survival rates of 86 and 90 percent, respectively.",
"   </p>",
"   <p>",
"    Approximately 30 to 50 percent of patients who relapse after chemotherapy and involved-field radiation therapy will respond to second line therapy. The response rate is probably higher for patients who relapse after chemotherapy alone, particularly if the relapse is confined to a site of initial disease involvement.",
"   </p>",
"   <p>",
"    Patients relapsing with early stage HL (Stages IA, IIA with no bulky disease or B symptoms) who had previously been treated with chemotherapy alone can have long term responses to chemotherapy plus involved-field radiotherapy. Patients past puberty are sometimes treated with radiotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients initially treated for advanced stage HL and those who relapse within three months of completing therapy need high dose chemotherapy and HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ACUTE EFFECTS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute effects of treatment for pediatric HL depend upon the specific chemotherapeutic agents used, the total dose of radiation therapy, and the volume irradiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Radiation effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute radiation effects are a function of the total dose delivered and the volume irradiated. The low-dose involved field radiation that is used in the treatment of pediatric HL is usually well tolerated. Toxic effects, which are usually self-limited and reversible, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperpigmentation of irradiated skin",
"     </li>",
"     <li>",
"      Transient hair thinning in exposed fields",
"     </li>",
"     <li>",
"      Mild gastrointestinal symptoms (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3847?source=see_link\">",
"       \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dry mouth or alteration in taste",
"     </li>",
"     <li>",
"      Granulocytopenia",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Chemotherapy effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who receive multiple chemotherapeutic agents for the treatment of HL may develop nausea and vomiting. These effects can be modulated with serotonin receptor antagonist anti-emetics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pretreatment with benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reversible alopecia is another acute effect of HL chemotherapy regimens. Other acute effects are related to particular agents. As examples,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    is associated with neurotoxicity;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    with pulmonary toxicity; and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    with cardiac toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H20#H20\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Vincristine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H36#H36\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Issues in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Myelosuppression and immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelosuppression is the most common dose-limiting acute toxicity of multiagent chemotherapy and can be treated with transfusions (red cells, platelets, granulocytes) or the administration of colony-stimulating factors (eg, erythropoietin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    ). Blood products, if given, need to be irradiated to prevent development of fatal transfusion-associated graft-versus-host disease in these immunocompromised subjects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27832?source=see_link&amp;anchor=H8#H8\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Irradiated red cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy-induced neutropenia and immunosuppression increase the risk of life-threatening infections with viruses, bacteria, and fungi, which need to be treated quickly and appropriately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15898?source=see_link&amp;anchor=H23804521#H23804521\">",
"     \"Fever in children with chemotherapy-induced neutropenia\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cellular immune system, including decreased T-cell and NK-cell function, may be impaired at baseline and further compromised by myelosuppression, increasing the susceptibility to herpes zoster and varicella infections. Post-exposure prophylaxis can be used to prevent development of varicella infection in children who did not receive the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    before undergoing chemotherapy. Antiviral therapy should be promptly initiated in patients who develop varicella infection or varicella zoster. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have undergone splenectomy or splenic irradiation are at particular risk for acquisition of serious bacterial infection and should receive prophylactic antibiotics and guidelines to follow during a febrile illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children and adolescents with HL have an excellent prognosis with current therapy. The overall five-year survival rate for early stage disease exceeds 90 percent, regardless of the therapeutic regimen chosen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/3,55-57\">",
"     3,55-57",
"    </a>",
"    ]. The overall five-year survival rate in patients with advanced stage disease who are treated with",
"    <span class=\"nowrap\">",
"     MOPP/ABVD",
"    </span>",
"    and involved field radiation is 93 to 97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1407816747\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have attempted to use prognostic factors to delineate a group of patients at high risk for first relapse who may benefit from more intensive initial therapy. Similarly, such factors may be able to identify a group of patients with an extremely low risk of relapse for whom therapy may be minimized. At this time the choice of initial therapy is principally based upon disease stage as described above. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A retrospective study evaluated prognostic factors in 328 children who had received combined modality treatment (CMT) for HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/58\">",
"     58",
"    </a>",
"    ]. Multivariate analysis revealed the following five adverse pretreatment factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Male sex",
"     </li>",
"     <li>",
"      Disease stages IIB, IIIB, or IV",
"     </li>",
"     <li>",
"      Bulky mediastinal disease",
"     </li>",
"     <li>",
"      White blood cell count",
"      <span class=\"nowrap\">",
"       &gt;13,500/microL",
"      </span>",
"     </li>",
"     <li>",
"      Hemoglobin concentration &lt;11.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A scoring system, giving one point for the presence of each of these factors, yielded five-year disease-free survivals as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 1 point: 94 percent",
"     </li>",
"     <li>",
"      2 points: 85 percent",
"     </li>",
"     <li>",
"      3 points: 71 percent",
"     </li>",
"     <li>",
"      4 to 5 points: 49 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate report in 195 children and young adults treated with CMT, the cumulative incidence of local failure (LF) was 11 percent at 5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/59\">",
"     59",
"    </a>",
"    ]. Predictors of LF included male sex, low initial hemoglobin level, and bulky mediastinal disease. B symptoms and elevated erythrocyte sedimentation rate have also been associated with a worse prognosis. One study showed that African-American patients had a poorer response than Caucasian patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above factors also have been found to predict for disease relapse in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link&amp;anchor=H9398216#H9398216\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Late complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the acute effects of chemotherapy and radiation, long-term survivors of HL may suffer from an array of unwanted side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/61-66\">",
"     61-66",
"    </a>",
"    ]. In a large retrospective study of pediatric cancer survivors that included data from 1876 HL survivors, the estimated cumulative incidence rates of total (grade 1 to 5) and severe (grade 3 to 5) chronic medical conditions in HL survivors were approximately 75 and 40 percent, respectively at 25 years follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/67\">",
"     67",
"    </a>",
"    ]. These complications have surfaced as significant causes of increased mortality among HL survivors, with deaths related to toxicities exceeding those from Hodgkin lymphoma after long-term follow-up. &nbsp;",
"   </p>",
"   <p>",
"    Late complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired growth of soft tissue and bones",
"     </li>",
"     <li>",
"      Thyroid dysfunction",
"     </li>",
"     <li>",
"      Gonadal dysfunction",
"     </li>",
"     <li>",
"      Cardiopulmonary toxicity",
"     </li>",
"     <li>",
"      Second malignancies",
"     </li>",
"     <li>",
"      Functional impairment and reduced overall general health",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these long-term effects were described initially following treatment regimens that are no longer used in children. As patients with HL were living longer, side effects from the chemotherapy, such as cardiopulmonary toxicity and second malignancies, emerged as a competing cause of delayed mortality (",
"    <a class=\"graphic graphic_figure graphicRef71648 \" href=\"mobipreview.htm?35/61/36829\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/66,68-70\">",
"     66,68-70",
"    </a>",
"    ]. The combined modality therapy regimens that are currently given were designed to be less intensive than the early therapies in an effort to decrease the incidence of adverse late effect. Longer follow-up is needed to fully assess the late complications of these regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term follow-up of pediatric HL patients should take place in a comprehensive pediatric oncology center, where late complications can best be anticipated, monitored, and treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/28,71\">",
"     28,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term effects on bone and soft-tissue growth among survivors of childhood HL are related to the dose and volume of received radiation, as well as the age of the child when the radiation was administered. As an example, in one study of 124 children with HL, prepubertal children who received &gt;33 Gy to the entire spine had an average height \"loss\" of 13 cm (2 SD of the United States population mean), whereas prepubertal children who received &lt;33 Gy and pubertal and postpubertal children who received &gt;33 Gy had little height impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/72\">",
"     72",
"    </a>",
"    ]. High-dose radiation can also cause narrowing of the thoracic apex with symmetric narrowing of the clavicles and atrophy of the soft tissues of the neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Thyroid dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid dysfunction (usually hypothyroidism) can occur in patients who have received radiation to the head and neck. The incidence varies from 4 to 79 percent, depending upon the radiation dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/30,73,74\">",
"     30,73,74",
"    </a>",
"    ]. Thyroid dysfunction occurs 1 to 10 years after radiation, and 20 to 30 percent of patients will need thyroid replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/63,66,75\">",
"     63,66,75",
"    </a>",
"    ]; the risk is probably life-long. Accordingly, survivors of childhood HL should be screened annually with a free T4 and TSH. Symptomatic patients should be evaluated sooner. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=see_link\">",
"     \"Endocrine surveillance in childhood cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Gonadal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadal dysfunction affects female as well as male survivors of childhood HL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic radiation carries a high likelihood of ablation of ovarian function. However, moving the ovaries out of the radiation field (oophoropexy) should preserve their function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/76-78\">",
"       76-78",
"      </a>",
"      ]. In addition, the successful reimplantation of cryopreserved ovarian cortical strips has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/79-81\">",
"       79-81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The testes are sensitive to radiotherapy and chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/82\">",
"       82",
"      </a>",
"      ]. Thus, in older patients with advanced stage disease, pretreatment storage of sperm should be considered, although decreased sperm quality has been documented before therapy in some cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children treated for HL before puberty should have annual ascertainment of Tanner stage to determine whether the pubertal status and tempo of progression are appropriate for age and height. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of serum luteinizing hormone (LH), follicle stimulating hormone (FSH), and sex steroid levels (testosterone or estradiol) should be performed in children with delayed or interrupted progression of puberty. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=see_link\">",
"     \"Endocrine surveillance in childhood cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7401?source=see_link\">",
"     \"Pubertal development and gonadal function in survivors of childhood cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Cardiopulmonary and cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term cardiopulmonary and cardiovascular complications of childhood HL therapy include cardiomyopathy, pericarditis, pulmonary fibrosis, and accelerated atherosclerosis, with increased risk of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/84-88\">",
"     84-88",
"    </a>",
"    ]. In one study of 1279 persons with Hodgkin lymphoma treated with mediastinal irradiation and followed for a median of 14.7 years, estimated cumulative incidence rates of clinically significant cardiac disease were 2, 5, 10, 16, and 23 percent at 5, 10, 15, 20, and 25 years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/89\">",
"     89",
"    </a>",
"    ]. The greatest excess cardiovascular risk was seen in those irradiated before the age of 20 years. The risk of cardiotoxicity may be lessened by reducing the dose of anthracycline chemotherapy and radiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H36#H36\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Issues in children'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic pulmonary complications of therapy for childhood HL include pulmonary fibrosis and spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40793?source=see_link\">",
"     \"Spontaneous pneumothorax in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No guidelines have been established for monitoring cardiopulmonary function in survivors of pediatric HL after completion of therapy. We perform electrocardiogram, echocardiogram, and pulmonary function tests yearly for the first five years after therapy and then every three to five years if no abnormalities are detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Second malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Childhood Cancer Survivor Study indicate that the incidence of second malignancies among survivors of HL and soft-tissue sarcomas is higher than that of other childhood cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/61,93\">",
"     61,93",
"    </a>",
"    ]. There is an 18.5-fold increased risk of developing a second cancer in HL patients compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/66,94\">",
"     66,94",
"    </a>",
"    ]. By 10 years after completing HL treatment, 10.6 percent will develop a second malignancy and 26.3 percent will by 30 years. Breast cancer, thyroid cancer, acute myeloid leukemia, and soft tissue sarcomas were the most common secondary malignances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/71,94-97\">",
"     71,94-97",
"    </a>",
"    ]. The latency for AML or myelodysplasia after HL is 3.2 years and 14.3 years for solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/98\">",
"     98",
"    </a>",
"    ]. Breast cancer incidence is directly related to the dose of radiation given with a 3.2-fold increased risk at 4 Gy and 8-fold increased risk when 40 Gy is given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Treatment-related AML is associated with the use of alkylating agents, anthracycline, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/6/32874/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group, and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    (Accessed January 19, 2010).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1407815048\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hodgkin lymphoma (HL, formerly called Hodgkin's disease) is a malignant lymphoma that accounts for approximately 7 percent of childhood cancers and 1 percent of childhood cancer deaths in the United States (",
"      <a class=\"graphic graphic_table graphicRef69839 \" href=\"mobipreview.htm?31/51/32572\">",
"       table 1",
"      </a>",
"      ). The incidence of HL in childhood varies by age such that HL is exceedingly rare in infants, but is the most common childhood cancer in the 15- to 19-year-old age group. (See",
"      <a class=\"local\" href=\"#H1407815041\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epstein-Barr virus (EBV) infection is associated with HL, can be detected in HRS cells, and is thought to play a role in the pathogenesis of HL. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Biology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The WHO classification of lymphomas divides HL into classical HL and nodular lymphocyte predominant HL (NLPHL). Classical HL occurs more commonly (90 to 95 percent of cases) than NLPHL and is subdivided into four subtypes, the most common of which is nodular sclerosis HL. (See",
"      <a class=\"local\" href=\"#H1407816399\">",
"       'Histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presenting symptoms and signs of HL in children include lymphadenopathy, systemic complaints, and mediastinal mass. HL almost always presents at a site above the diaphragm, with only approximately three percent of cases presenting in a subdiaphragmatic location. (See",
"      <a class=\"local\" href=\"#H1407815786\">",
"       'Presenting symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected HL should have a complete evaluation at a comprehensive pediatric oncology center prior to beginning treatment. The goal is to confirm the diagnosis and evaluate the extent of disease, which, in turn, determines the clinical and pathologic stage, treatment, and to a great extent, prognosis (",
"      <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of HL depends upon the extent of disease (",
"      <a class=\"graphic graphic_table graphicRef85775 \" href=\"mobipreview.htm?17/13/17629\">",
"       table 4",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with low risk HL (Ann Arbor stage IA, IIA, and sometimes IIIA) are usually treated with combination chemotherapy followed by low dose involved field radiation. Using this approach, the overall five-year survival rate is &gt;95 percent. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Low risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with intermediate and high risk HL have conventionally been treated with more intensive combination chemotherapy plus involved field radiation. The overall five-year survival rate with this approach exceeds 90 percent. (See",
"      <a class=\"local\" href=\"#H9978541\">",
"       'Intermediate risk disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'High risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with relapsed or refractory disease are treated with non-cross-resistant combination chemotherapy, sometimes followed by autologous hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Relapsed or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute effects of treatment for pediatric HL depend upon the specific chemotherapy agents used, the total dose of radiation therapy, and the volume irradiated. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Acute effects of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term follow-up of pediatric HL patients should take place in a comprehensive pediatric oncology center, where late complications can best be anticipated, monitored, and treated. Late effects of treatment for pediatric HL include impaired growth of soft tissue and bones, thyroid dysfunction, gonadal dysfunction, cardiopulmonary toxicity, second malignancies, functional impairment, and reduced overall general health. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Late complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Trends in childhood cancer mortality--United States, 1990-2004. MMWR Morb Mortal Wkly Rep 2007; 56:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/2\">",
"      Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008; 112:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/3\">",
"      Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010; 28:2625.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Kosary CL, Hankey BF, et al. (Eds). SEER cancer statistics review: 1973-1994. NIH publ no. 97-2789. Bethesda: National Cancer Institute, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/5\">",
"      Correa P, O'Conor GT. Epidemiologic patterns of Hodgkin's disease. Int J Cancer 1971; 8:192.",
"     </a>",
"    </li>",
"    <li>",
"     Percy CL, Smith MA, Linet M. Lymphomas and reticuloendothelial neoplasms. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith MA, Gurney JG, et al. (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/7\">",
"      Ferraris AM, Racchi O, Rapezzi D, et al. Familial Hodgkin's disease: a disease of young adulthood? Ann Hematol 1997; 74:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/8\">",
"      Crump C, Sundquist K, Sieh W, et al. Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood. Am J Epidemiol 2012; 176:1147.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/10\">",
"      Krikorian JG, Portlock CS, Mauch PM. Hodgkin's disease presenting below the diaphragm: a review. J Clin Oncol 1986; 4:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/11\">",
"      Kebudi R, Ayan I, Erseven G, et al. Hypertrophic osteoarthropathy and intrathoracic Hodgkin disease of childhood. Med Pediatr Oncol 1997; 29:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/12\">",
"      Atkinson MK, McElwain TJ, Peckham MJ, Thomas PP. Hypertrophic pulmonary osteoarthropathy in Hodgkin's disease: reversal with chemotherapy. Cancer 1976; 38:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/13\">",
"      Ansari N, Qureshi A, Hall GW. Images in haematology. Hypertrophic pulmonary osteoarthropathy in mediastinal Hodgkin lymphoma in childhood. Br J Haematol 2010; 150:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/14\">",
"      Seymour JF. Splenomegaly, eosinophilia, and pruritus: Hodgkin's disease, or...? Blood 1997; 90:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/15\">",
"      Olsson H, Brandt L. Relief of pruritus as an early sign of spinal cord compression in Hodgkin's disease. Acta Med Scand 1979; 206:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/16\">",
"      Stefanato CM, Reyes-Mugica M. Masked Hodgkin's disease: the pruriginous disguise. Pediatr Hematol Oncol 1996; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/17\">",
"      Cavalli F. Rare syndromes in Hodgkin's disease. Ann Oncol 1998; 9 Suppl 5:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/18\">",
"      Callahan BC, Coe R, Place HM. Hodgkin disease of the spine presenting as alcohol-related pain. A case report and review of the literature. J Bone Joint Surg Am 1994; 76:119.",
"     </a>",
"    </li>",
"    <li>",
"     Sills RH. The spleen and lymph nodes. In: Oski's Pediatrics. Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.1717.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/20\">",
"      Heiberg E, Wolverson MK, Sundaram M, Nouri S. Normal thymus: CT characteristics in subjects under age 20. AJR Am J Roentgenol 1982; 138:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/21\">",
"      Murphy SB. The national impact of clinical cooperative group trials for pediatric cancer. Med Pediatr Oncol 1995; 24:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/22\">",
"      Mahoney DH Jr, Schreuders LC, Gresik MV, McClain KL. Role of staging bone marrow examination in children with Hodgkin disease. Med Pediatr Oncol 1998; 30:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/23\">",
"      Rostock RA, Siegelman SS, Lenhard RE, et al. Thoracic CT scanning for mediastinal Hodgkin's disease: results and therapeutic implications. Int J Radiat Oncol Biol Phys 1983; 9:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/24\">",
"      Baker LL, Parker BR, Donaldson SS, Castellino RA. Staging of Hodgkin disease in children: comparison of CT and lymphography with laparotomy. AJR Am J Roentgenol 1990; 154:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/25\">",
"      Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin's lymphoma. Pediatr Radiol 2004; 34:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/26\">",
"      Hernandez-Pampaloni M, Takalkar A, Yu JQ, et al. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 2006; 36:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/27\">",
"      Robertson VL, Anderson CS, Keller FG, et al. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2011; 80:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/28\">",
"      Corrigan JJ, Feig SA, American Academy of Pediatrics. Guidelines for pediatric cancer centers. Pediatrics 2004; 113:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/29\">",
"      Foltz LM, Song KW, Connors JM. Hodgkin's lymphoma in adolescents. J Clin Oncol 2006; 24:2520.",
"     </a>",
"    </li>",
"    <li>",
"     Hudson MM, Donaldson SS. Hodgkin's disease. In: Principles and Practice of Pediatric Oncology, 5th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.695.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/31\">",
"      Yung L, Smith P, Hancock BW, et al. Long term outcome in adolescents with Hodgkin's lymphoma: poor results using regimens designed for adults. Leuk Lymphoma 2004; 45:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/32\">",
"      Ruhl U, Albrecht MR, Lueders H, et al. The German Multinational GPOH-HD 95 trial: Treatment results and analysis of failures in pediatric Hodgkins disease using combination chemotherapy with and without radiation (abstract). Int J Radiat Oncol Biol Phys 2004; 60:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/33\">",
"      Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/34\">",
"      Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/35\">",
"      Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006; 46:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/36\">",
"      Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/37\">",
"      R&uuml;hl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001; 51:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/38\">",
"      Friedman DI, Wolden S, Constine L, et al. AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group. Blood 2010; 116:Abstract 766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/39\">",
"      Mauz-K&ouml;rholz C, Hasenclever D, D&ouml;rffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28:3680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/40\">",
"      Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011; 117:2596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/41\">",
"      Friedmann AM, Hudson MM, Weinstein HJ, et al. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 2002; 20:3088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/42\">",
"      Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004; 22:4541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/43\">",
"      Shankar A, Visaduraki M, Hayward J, et al. Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone - the results of the United Kingdom HD3 national cohort trial. Eur J Cancer 2012; 48:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/44\">",
"      Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/45\">",
"      Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol 2001; 23:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/46\">",
"      Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol 1998; 103:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/47\">",
"      Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/48\">",
"      Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22:4532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/49\">",
"      Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011; 17:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/50\">",
"      Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/51\">",
"      Morabito F, Stelitano C, Luminari S, et al. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Bone Marrow Transplant 2006; 37:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/52\">",
"      Schellong G, D&ouml;rffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23:6181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/53\">",
"      Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/54\">",
"      Wirth A, Corry J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1997; 39:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/55\">",
"      Thomson AB, Wallace WH. Treatment of paediatric Hodgkin's disease. a balance of risks. Eur J Cancer 2002; 38:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/56\">",
"      Johnston WT, Lightfoot TJ, Simpson J, Roman E. Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol 2010; 34:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/57\">",
"      Pinkerton R, Wills RA, Coory MD, Fraser CJ. Survival from haematological malignancy in childhood, adolescence and young adulthood in Australia: is the age-related gap narrowing? Med J Aust 2010; 193:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/58\">",
"      Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003; 21:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/59\">",
"      Krasin MJ, Rai SN, Kun LE, et al. Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: local disease control with combined-modality therapy. J Clin Oncol 2005; 23:8406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/60\">",
"      Metzger ML, Castellino SM, Hudson MM, et al. Effect of race on the outcome of pediatric patients with Hodgkin's lymphoma. J Clin Oncol 2008; 26:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/61\">",
"      Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/62\">",
"      Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/63\">",
"      Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 1989; 16:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/64\">",
"      Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003; 290:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/65\">",
"      Kadan-Lottick NS, Zeltzer LK, Liu Q, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 2010; 102:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/66\">",
"      Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011; 117:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/67\">",
"      Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/68\">",
"      Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects. Cancer J Sci Am 1999; 5:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/69\">",
"      Schellong G. Pediatric Hodgkin's disease: treatment in the late 1990s. Ann Oncol 1998; 9 Suppl 5:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/70\">",
"      Chow LM, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006; 24:5735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/71\">",
"      Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998; 16:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/72\">",
"      Willman KY, Cox RS, Donaldson SS. Radiation induced height impairment in pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994; 28:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/73\">",
"      Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer 1984; 53:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/74\">",
"      Samaan NA, Schultz PN, Yang KP, et al. Endocrine complications after radiotherapy for tumors of the head and neck. J Lab Clin Med 1987; 109:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/75\">",
"      Shafford EA, Kingston JE, Healy JC, et al. Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin's disease. Br J Cancer 1999; 80:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/76\">",
"      Thibaud E, Ramirez M, Brauner R, et al. Preservation of ovarian function by ovarian transposition performed before pelvic irradiation during childhood. J Pediatr 1992; 121:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/77\">",
"      Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer 1999; 86:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/78\">",
"      Le Floch O, Donaldson SS, Kaplan HS. Pregnancy following oophoropexy and total nodal irradiation in women with Hodgkin's disease. Cancer 1976; 38:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/79\">",
"      Radford JA, Lieberman BA, Brison DR, et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet 2001; 357:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/80\">",
"      Demeestere I, Simon P, Emiliani S, et al. Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease. Oncologist 2007; 12:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/81\">",
"      Oktay K, T&uuml;rk&ccedil;&uuml;o��lu I, Rodriguez-Wallberg KA. Four spontaneous pregnancies and three live births following subcutaneous transplantation of frozen banked ovarian tissue: what is the explanation? Fertil Steril 2011; 95:804.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/82\">",
"      Ben Arush MW, Solt I, Lightman A, et al. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 2000; 17:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/83\">",
"      Botchan A, Hauser R, Gamzu R, et al. Sperm quality in Hodgkin's disease versus non-Hodgkin's lymphoma. Hum Reprod 1997; 12:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/84\">",
"      Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/85\">",
"      Scholz KH, Herrmann C, Tebbe U, et al. Myocardial infarction in young patients with Hodgkin's disease--potential pathogenic role of radiotherapy, chemotherapy, and splenectomy. Clin Investig 1993; 71:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/86\">",
"      Hicks GL Jr. Coronary artery operation in radiation-associated atherosclerosis: long-term follow-up. Ann Thorac Surg 1992; 53:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/87\">",
"      Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/88\">",
"      Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23:6508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/89\">",
"      Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/90\">",
"      Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep 1982; 66:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/91\">",
"      Bossi G, Cerveri I, Volpini E, et al. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann Oncol 1997; 8 Suppl 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/92\">",
"      Marina NM, Greenwald CA, Fairclough DL, et al. Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 1995; 75:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/93\">",
"      O'Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010; 28:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/94\">",
"      Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21:4386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/95\">",
"      Hudson MM, Poquette CA, Lee J, et al. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 1998; 16:3592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/96\">",
"      Lin HM, Teitell MA. Second malignancy after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol 2005; 27:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/97\">",
"      Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol 2005; 23:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/98\">",
"      van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/99\">",
"      Alm El-Din MA, Hughes KS, Finkelstein DM, et al. Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys 2009; 73:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/100\">",
"      Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010; 152:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/6/32874/abstract/101\">",
"      Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique. J Clin Oncol 2003; 21:1074.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6246 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32874=[""].join("\n");
var outline_f32_6_32874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1407815048\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1407815041\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Familial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1407816399\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1407816406\">",
"      Classical HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1407816413\">",
"      Nodular lymphocyte predominant HL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1407815786\">",
"      PRESENTING SYMPTOMS AND SIGNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hepatosplenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mediastinal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H735857\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Low risk disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9978541\">",
"      Intermediate risk disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      High risk disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Relapsed or refractory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ACUTE EFFECTS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Radiation effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Chemotherapy effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Myelosuppression and immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1407816747\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Late complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Growth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Gonadal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Cardiopulmonary and cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Second malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1407815048\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6246\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6246|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/42/30383\" title=\"figure 1\">",
"      Age distribution in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/31/10743\" title=\"figure 2\">",
"      Mediastinal mass compartment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/2/42021\" title=\"figure 3\">",
"      Lymph node regions lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/61/36829\" title=\"figure 4\">",
"      Mortality in Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6246|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/18/42276\" title=\"picture 1\">",
"      Reed Sternberg cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/58/28578\" title=\"picture 2\">",
"      Reed Sternberg variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6246|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/51/32572\" title=\"table 1\">",
"      Common childhood cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/23/17788\" title=\"table 2\">",
"      Hodgkin immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/23/19836\" title=\"table 3\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/13/17629\" title=\"table 4\">",
"      Risk-adapted treatment of newly diagnosed HL in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/34/12840?source=related_link\">",
"      Approach to the child with an enlarged spleen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=related_link\">",
"      Endocrine surveillance in childhood cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21274?source=related_link\">",
"      Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7401?source=related_link\">",
"      Pubertal development and gonadal function in survivors of childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3847?source=related_link\">",
"      Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40793?source=related_link\">",
"      Spontaneous pneumothorax in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/23/2426?source=related_link\">",
"      The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3703?source=related_link\">",
"      The role of Epstein-Barr virus in Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34520?source=related_link\">",
"      Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_6_32875="Tips on taking medicines PI";
var content_f32_6_32875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips on taking medicines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        To get the most out of your medicines, follow these tips:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Take your medicines every day, as instructed, and at the same time every day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use tools, such as a daily or weekly pill box, to organize your medicines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Create reminders for yourself to take your medicines. Try using a calendar, post-it notes, a digital watch, or whatever method might work for you.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If your doctor or pharmacist gave you written instructions on how to take your medicines, put the instructions in a place where you can easily see them every day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not skip pills, change doses, or take extra pills unless your doctor tells you to.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Learn how each of your medicines works and why you take it. People who understand their medicines are more likely to stay on them.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tell your doctor or nurse about any side effects you have. He or she might have ways to reduce or get rid of the side effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tell your doctor, nurse, or pharmacist if you can't afford your medicines. There are often ways to reduce costs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make a list of all the medicines you take and keep one copy at home and one in your wallet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Talk to your doctor, nurse, or pharmacist",
"        <strong>",
"         before",
"        </strong>",
"        you take any cough, cold, allergy, pain, or other extra medicines. The same goes for supplements and herbal medicines. Over-the-counter and herbal medicines can interact with prescription medicines.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32875=[""].join("\n");
var outline_f32_6_32875=null;
var title_f32_6_32876="Causes of weight loss in children and adolescents";
var content_f32_6_32876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of weight loss in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Causes of weight loss in infants over six months of age, children, and adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Life-threatening conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eating disorders with complications (eg, anorexia nervosa, bulimia nervosa, fad diets)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dehydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Common conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Viral gastroenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Child neglect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malnutrition and failure to thrive (children &le;3 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lactose intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug use (eg, amphetamines, methylphenidate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human immunodeficiency virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other chronic infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giardiasis and other intestinal parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Superior mesenteric artery syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclic vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatologic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypercalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32876=[""].join("\n");
var outline_f32_6_32876=null;
var title_f32_6_32877="Meds for conscious sedation";
var content_f32_6_32877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous medications used for sedation and analgesia in endoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose (adult)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Repeat dose",
"        <sup>",
"         &bull;",
"        </sup>",
"        (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Midazolam",
"       </td>",
"       <td>",
"        0.02 to 0.03 mg/kg (1 to 2 mg) over 2 to 3 minutes",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        15-80",
"       </td>",
"       <td>",
"        2-5",
"       </td>",
"       <td>",
"        Sedative, amnestic, anxiolytic. Non-analgesic. Delayed recovery in older adults, with obesity or impaired hepatic function. Reduce dose in combination with opiate analgesic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lorazepam",
"       </td>",
"       <td>",
"        0.044 mg/kg (2 to 4 mg) over 1 to 2 minutes",
"       </td>",
"       <td>",
"        15-20",
"       </td>",
"       <td>",
"        360-480",
"       </td>",
"       <td>",
"        15-20",
"       </td>",
"       <td>",
"        Sedative, amnestic, anxiolytic. Prolonged onset, slow recovery, variable response.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diazepam",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.03-0.1 mg/kg (5 to 10 mg) over 2 to 3 minutes",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        360",
"       </td>",
"       <td>",
"        2-5",
"       </td>",
"       <td>",
"        Sedative, amnestic, anxiolytic. Phlebitis, IV incompatibility, prolonged onset, slow recovery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Opiate analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fentanyl",
"       </td>",
"       <td>",
"        0.5 to 1 micrograms/kg over 3 or more minutes",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        30-60",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Sedative, analgesic. Non-amnestic. Minimal hypotension and histamine release. Reduce dose in combination with benzodiazepine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Morphine",
"       </td>",
"       <td>",
"        2.5 to 5 mg over 3 to 5 minutes",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        120-240",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        Sedative, analgesic. Histamine release, hypotension. Prolonged duration and recovery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meperidine",
"       </td>",
"       <td>",
"        25 to 50 mg over 3 to 5 minutes",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        60-180",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        Sedative, analgesic. Histamine release, hypotension, nausea. Prolonged duration and recovery. Interaction with MAO inhibitors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Sedative-hypnotic anesthetic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propofol continuous infusion",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Initiate infusion at 25 micrograms/kg per minute; titrate gradually to response (consult detailed reference)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        ~3-10 upon discontinuation",
"       </td>",
"       <td>",
"        Continuous infusion",
"       </td>",
"       <td>",
"        Sedative, amnestic. Non-analgesic. Rapid onset and neurological recovery upon discontinuation. Respiratory depression, O",
"        <sub>",
"         2",
"        </sub>",
"        desaturation, apnea, hypotension with overly rapid administration. Injection site pain. Older adults: reduce dose by 20 percent. Contains egg lecithin, soybean oil (potential allergens).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Antagonist agents for reversal of overdose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Naloxone",
"       </td>",
"       <td>",
"        0.1 to 0.2 mg",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        45-120",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"       <td>",
"        Overcomes respiratory depression, sedation and hypotension of opiates. Reverses analgesia. Acute narcotic withdrawal if tolerant.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flumazenil",
"       </td>",
"       <td>",
"        0.2 mg over 30 seconds",
"       </td>",
"       <td>",
"        1-3 (peak 6-10)",
"       </td>",
"       <td>",
"        ~60",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Overcomes sedation and partially reverses respiratory depression of benzodiazepines. Agitation, acute withdrawal and risk of withdrawal seizures if benzodiazepine tolerant.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Initial dose for healthy adult &lt;60 years of age. Older, debilitated persons and/or those with compromised cardiorespiratory function or hepatic or renal insufficiency are at increased risk of adverse events with these agents and dosing should be adjusted accordingly. See text for details.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Sedatives and analgesics: repeat one-half initial dose at interval noted if needed to achieve desired depth and duration of sedation. Additional titration may be needed.",
"      <br>",
"       &Delta; Dose for conventional (non-emulsion) diazepam injection. Diazepam emulsion is not available in United States.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Bolus injection of propofol alone or in combination with small doses of an opiate and/or benzodiazepine is commonly practiced as an alternative to administration by IV infusion. When given as a bolus, it should be administered by an anesthesiologist or certified registered nurse anesthetist.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Cohen LB, DeLegge MH, Aisenberg J, et al. AGA institute review of endoscopic sedation. Gastroenterology 2007; 133:675.",
"      </li>",
"      <li>",
"       Gahart BL, Nazareno AR. Intravenous medications 27th ed, Mosby Elsevier, St. Louis, MO 2011.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32877=[""].join("\n");
var outline_f32_6_32877=null;
var title_f32_6_32878="2010 revised criteria for diagnosis of ARVC";
var content_f32_6_32878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2010 revised Task Force criteria for the diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Revised Task Force criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        I. Global or regional dysfunction and structural alterations*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Major",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          By 2D echo:",
"         </strong>",
"        </p>",
"        <p>",
"         &bull; Regional RV akinesia, dyskinesia, or aneurysm",
"        </p>",
"        <p>",
"         &bull;",
"         <em>",
"          and",
"         </em>",
"         1 of the following (end diastole):",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- PLAX RVOT &ge;32 mm (corrected for body size [PLAX/BSA] &ge;19 mm/m",
"         <sup>",
"          2",
"         </sup>",
"         )",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- PSAX RVOT &ge;36 mm (corrected for body size [PSAX/BSA] &ge;21 mm/m",
"         <sup>",
"          2",
"         </sup>",
"         )",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;-",
"         <em>",
"          or",
"         </em>",
"         fractional area change &le;33 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          By MRI:",
"         </strong>",
"        </p>",
"        <p>",
"         &bull; Regional RV akinesia or dyskinesia or dyssynchronous RV contraction",
"        </p>",
"        <p>",
"         &bull;",
"         <em>",
"          and",
"         </em>",
"         1 of the following:",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- Ratio of RV end-diastolic volume to BSA &ge;110 mL/m",
"         <sup>",
"          2",
"         </sup>",
"         (male) or &ge;100 mL/m",
"         <sup>",
"          2",
"         </sup>",
"         (female)",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;-",
"         <em>",
"          or",
"         </em>",
"         RV ejection fraction &le;40 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          By RV angiography:",
"         </strong>",
"        </p>",
"        <p>",
"         &bull; Regional RV akinesia, dyskinesia, or aneurysm",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Minor",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          By 2D echo:",
"         </strong>",
"        </p>",
"        <p>",
"         &bull; Regional RV akinesia or dyskinesia",
"        </p>",
"        <p>",
"         &bull;",
"         <em>",
"          and",
"         </em>",
"         1 of the following (end diastole):",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- PLAX RVOT &ge;29 to &lt;32 mm (corrected for body size [PLAX/BSA] &ge;16 to &lt;19 mm/m",
"         <sup>",
"          2",
"         </sup>",
"         )",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- PSAX RVOT &ge;32 to &lt;36 mm (corrected for body size [PSAX/BSA] &ge;18 to &lt;21 mm/m",
"         <sup>",
"          2",
"         </sup>",
"         )",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;-",
"         <em>",
"          or",
"         </em>",
"         fractional area change &gt;33 percent to &le;40 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          By MRI:",
"         </strong>",
"        </p>",
"        <p>",
"         &bull; Regional RV akinesia or dyskinesia or dyssynchronous RV contraction",
"        </p>",
"        <p>",
"         &bull;",
"         <em>",
"          and",
"         </em>",
"         1 of the following:",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- Ratio of RV end-diastolic volume to BSA &ge;100 to &lt;110 mL/m",
"         <sup>",
"          2",
"         </sup>",
"         (male) or &ge;90 to &lt;100 mL/m",
"         <sup>",
"          2",
"         </sup>",
"         (female)",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;-",
"         <em>",
"          or",
"         </em>",
"         RV ejection fraction &gt;40 percent to &le;45 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        II. Tissue characterization of wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Major",
"        </strong>",
"       </td>",
"       <td>",
"        &bull; Residual myocytes &lt;60 percent by morphometric analysis (or &lt;50 percent if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Minor",
"        </strong>",
"       </td>",
"       <td>",
"        &bull; Residual myocytes 60 percent to 75 percent by morphometric analysis (or 50 percent to 65 percent if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        III. Repolarization abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Major",
"        </strong>",
"       </td>",
"       <td>",
"        &bull; Inverted T waves in right precordial leads (V",
"        <sub>",
"         1",
"        </sub>",
"        , V",
"        <sub>",
"         2",
"        </sub>",
"        , and V",
"        <sub>",
"         3",
"        </sub>",
"        ) or beyond in individuals &gt;14 years of age (in the absence of complete right bundle-branch block QRS &ge;120 ms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Minor",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Inverted T waves in leads V",
"         <sub>",
"          1",
"         </sub>",
"         and V",
"         <sub>",
"          2",
"         </sub>",
"         in individuals &gt;14 years of age (in the absence of complete right bundle-branch block) or in V",
"         <sub>",
"          4",
"         </sub>",
"         , V",
"         <sub>",
"          5",
"         </sub>",
"         , or V",
"         <sub>",
"          6",
"         </sub>",
"        </p>",
"        <p>",
"         &bull; Inverted T waves in leads V",
"         <sub>",
"          1",
"         </sub>",
"         , V",
"         <sub>",
"          2",
"         </sub>",
"         , V",
"         <sub>",
"          3",
"         </sub>",
"         , and V",
"         <sub>",
"          4",
"         </sub>",
"         in individuals &gt;14 years of age in the presence of complete right bundle-branch block",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        IV. Depolarization/conduction abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Major",
"        </strong>",
"       </td>",
"       <td>",
"        &bull; Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V",
"        <sub>",
"         1",
"        </sub>",
"        to V",
"        <sub>",
"         3",
"        </sub>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Minor",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Late potentials by SAECG in &ge;1 of the following 3 parameters in the absence of a QRS duration of &ge;110 ms on the standard ECG",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- Filtered QRS duration (fQRS) &ge;114 ms",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- Duration of terminal QRS &lt;40 &micro;V (low-amplitude signal duration) &ge;38 ms",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;- Root-mean-square voltage of terminal 40 ms &le;20 &micro;V",
"        </p>",
"        <p>",
"         &bull; Terminal activation duration of QRS &ge;55 ms measured from the nadir of the S wave to the end of the QRS, including R', in V",
"         <sub>",
"          1",
"         </sub>",
"         , V",
"         <sub>",
"          2",
"         </sub>",
"         , or V",
"         <sub>",
"          3",
"         </sub>",
"         , in the absence of complete right bundle-branch block",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        V. Arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Major",
"        </strong>",
"       </td>",
"       <td>",
"        &bull; Nonsustained or sustained ventricular tachycardia of left bundle-branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Minor",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis",
"        </p>",
"        <p>",
"         &bull; &gt;500 ventricular extrasystoles per 24 hours (Holter)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        VI. Family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Major",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; ARVC/D confirmed in a first-degree relative who meets current Task Force criteria",
"        </p>",
"        <p>",
"         &bull; ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative",
"        </p>",
"        <p>",
"         &bull; Identification of a pathogenic mutation&Delta; categorized as associated or probably associated with ARVC/D in the patient under evaluation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Minor",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria",
"        </p>",
"        <p>",
"         &bull; Premature sudden death (&lt;35 years of age) due to suspected ARVC/D in a first-degree relative",
"        </p>",
"        <p>",
"         &bull; ARVC/D confirmed pathologically or by current Task Force Criteria in second-degree relative",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagnostic terminology for revised criteria:",
"    <br>",
"     <br>",
"      <ul>",
"       <li>",
"        Definite diagnosis: 2 Major,&nbsp;OR 1 Major and 2 Minor criteria, OR 4 Minor from different categories",
"       </li>",
"       <li>",
"        Borderline diagnosis: 1 Major and 1 Minor, OR 3 Minor criteria from different categories",
"       </li>",
"       <li>",
"        Possible diagnosis: 1 Major, OR 2 Minor criteria from different categories",
"       </li>",
"      </ul>",
"      <p>",
"       &nbsp;",
"      </p>",
"      <div class=\"footnotes\">",
"       PLAX: parasternal long-axis view; RVOT: RV outflow tract; BSA: body surface area; PSAX: parasternal short-axis view; aVF: augmented voltage unipolar left foot lead; aVL: augmented voltage unipolar left arm lead.",
"       <br>",
"        * Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the proposed modified criteria.",
"        <br>",
"         &Delta; A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded protein, is unobserved or rare in a large non-ARVC/D control population, and either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree.",
"        </br>",
"       </br>",
"      </div>",
"      <div class=\"reference\">",
"       Modified with permission from: Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force criteria. Circulation 2010; 121:1533. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32878=[""].join("\n");
var outline_f32_6_32878=null;
var title_f32_6_32879="Spiral frac tibial shaft";
var content_f32_6_32879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A spiral fracture of the tibial shaft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eiff, MP, Hatch, RL, Calmbach, WL. Fracture management for primary care, 2nd ed. Chapter 2: General principles of fracture care. Saunders, Philadelphia 1998. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy;1998 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_6_32879=[""].join("\n");
var outline_f32_6_32879=null;
